[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 443
1. Lee JH, Lee JH, Kim A, Kim I, Chae YS: Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas. Pathol Int; 2005 Jul;55(7):386-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of salivary gland carcinoma is often difficult because of the confusing histopathological features of the different types of salivary gland carcinomas.
  • The expression of MUC3, MUC5AC, MUC6, cytokeratin (CK)7 and CK20 was studied in 20 mucoepidermoid carcinomas (MEC), 20 adenoid cystic carcinomas (AdCC), and 11 acinic cell carcinomas (ACC).
  • All cases (100%) of AdCC were negative for MUC3, MUC5AC and MUC6.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Keratin-20. Keratin-7. Keratins / biosynthesis. Male. Middle Aged. Mucin 5AC. Mucin-3. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982212.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-3; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


2. Li N, Yang Y, Bu J, Zhao C, Lu S, Zhao J, Yan L, Cui L, Zheng R, Li J, Tang J, Zhao K: An autosomal dominant progressive congenital zonular nuclear cataract linked to chromosome 20p12.2-p11.23. Mol Vis; 2006;12:1506-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To map and to identify the causal gene for autosomal dominant congenital cataract (ADCC) in a Chinese family.
  • CONCLUSIONS: We have mapped the genetic locus of ADPCZNC to chromosome 20p12.2-p11.23 in an ADCC family.


3. Wang YJ, Xu DM, Cui J, Wang ZQ: [Effect of pregnancy on the immune response against Trichinella spiralis infection in mice]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2009 Feb 28;27(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ability of sera from infected pregnant mice to mediate the death of pre-encapsulated larvae (PEL) were assayed in an antibody-dependent cell-mediated cytotoxicity (ADCC).
  • The ability of sera to mediate the death of pre-encapsulate larvae in ADCC was significantly higher in pregnant mice (42.6%) than in virgin mice (26.9%) at 2 weeks after infection (F=1.195, P<0.05).
  • CONCLUSION: Pregnancy has a synergetic effect on immune response of mice against T. spiralis infection, which may be related with the increased level of serum anti-Trichinella antibody and enhanced ability of sera in mediating the death of pre-encapsulated larvae in ADCC.

  • MedlinePlus Health Information. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19459500.001).
  • [ISSN] 1000-7423
  • [Journal-full-title] Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases
  • [ISO-abbreviation] Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Helminth
  •  go-up   go-down


Advertisement
4. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS: CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma; 2007 Dec;48(12):2424-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant alemtuzumab-associated complement-mediated cell lysis (CMC) or antibody-dependent cellular cytotoxicity (ADCC) was demonstrated in RSCL.
  • In contrast, in vitro exposure of RRCL to alemtuzumab resulted in a significant degree of CMC and ADCC.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067019.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA103985-1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Histocompatibility Antigens Class II; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


5. Richardson SJ, Eve HE, Copplestone JA, Dyer MJ, Rule SA: Activity of thalidomide and lenalidomide in mantle cell lymphoma. Acta Haematol; 2010;123(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab induces both complement-dependent and antibody-dependent cellular cytotoxicity (ADCC) against MCL cells.
  • Rituximab-induced ADCC is enhanced by lenalidomide and, to a lesser extent, thalidomide.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 S. Karger AG, Basel.
  • (PMID = 19907157.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 9007-36-7 / Complement System Proteins; F0P408N6V4 / lenalidomide
  •  go-up   go-down


6. Schuster M, Jost W, Mudde GC, Wiederkum S, Schwager C, Janzek E, Altmann F, Stadlmann J, Stemmer C, Gorr G: In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J; 2007 Jun;2(6):700-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have demonstrated that the reduction of the core fucosylation on N-glycans of human IgGs is responsible for a clearly enhanced antibody-dependent cellular cytotoxicity (ADCC).
  • Antibodies transiently expressed and secreted by such genetically modified moss protoplasts assembled correctly, showed an unaltered antigen-binding affinity and, in extensive tests, revealed an up to 40-fold enhanced ADCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427997.001).
  • [ISSN] 1860-7314
  • [Journal-full-title] Biotechnology journal
  • [ISO-abbreviation] Biotechnol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / IGN 311; 0 / Polysaccharides
  •  go-up   go-down


7. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M: Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol; 2009 Mar 15;182(6):3718-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because the macaques lacked SHIV(89.6P)-neutralizing activity prechallenge, we investigated whether Ab-dependent cellular cytotoxicity (ADCC) and Ab-dependent cell-mediated viral inhibition (ADCVI) might exert a protective effect.
  • We clearly show that Tat can serve as an ADCC target, although the Tat-specific activity elicited did not correlate with better protection.
  • However, Env-specific ADCC activity was consistently higher in the Tat/Env group, with sustained cell killing postchallenge exhibited at higher levels (p < 0.00001) for a longer duration (p = 0.0002) compared with the multigenic group.
  • The higher ADCC and ADCVI activities seen in the Tat/Env group provide a plausible mechanism responsible for the greater chronic-phase protection.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2007 Apr;81(7):3414-27 [17229693.001]
  • [Cites] J Immunol. 2007 May 15;178(10):6596-603 [17475891.001]
  • [Cites] Curr HIV Res. 2007 Nov;5(6):642-55 [18045119.001]
  • [Cites] Vaccine. 2008 Jan 30;26(5):727-37 [18096278.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Apr;24(4):587-94 [18366309.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2207-9 [18832884.001]
  • [Cites] Vaccine. 2003 Sep 8;21(25-26):4022-35 [12922139.001]
  • [Cites] J Virol. 2004 Mar;78(5):2212-21 [14963117.001]
  • [Cites] J Virol. 2004 Jul;78(14):7490-7 [15220422.001]
  • [Cites] Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S105-17 [15285710.001]
  • [Cites] Science. 1985 Jul 5;229(4708):69-73 [2990040.001]
  • [Cites] Nature. 1986 Mar 27-Apr 2;320(6060):367-71 [3007995.001]
  • [Cites] AIDS Res Hum Retroviruses. 1987;3(4):409-22 [2833917.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1189-93 [2849510.001]
  • [Cites] Clin Exp Immunol. 1988 Sep;73(3):343-7 [3208446.001]
  • [Cites] Clin Exp Immunol. 1989 Feb;75(2):184-9 [2649286.001]
  • [Cites] AIDS. 1989 May;3(5):273-6 [2548535.001]
  • [Cites] AIDS Res Hum Retroviruses. 1989 Dec;5(6):557-63 [2692657.001]
  • [Cites] J Clin Immunol. 1989 Nov;9(6):454-61 [2576558.001]
  • [Cites] AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56 [1971182.001]
  • [Cites] J Med Virol. 1990 Mar;30(3):163-8 [2341832.001]
  • [Cites] Clin Exp Immunol. 1990 Jul;81(1):5-10 [2379323.001]
  • [Cites] J Immunol. 1990 Nov 15;145(10):3276-82 [1700004.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4481-5 [8402618.001]
  • [Cites] Vaccine. 1993 Sep;11(12):1240-6 [8256505.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 May;7(5):428-37 [7908983.001]
  • [Cites] Science. 1995 Apr 21;268(5209):429-31 [7716549.001]
  • [Cites] Gene Ther. 1994 May;1(3):208-16 [7584083.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):408-16 [7583436.001]
  • [Cites] J Virol. 1996 Mar;70(3):1384-9 [8627654.001]
  • [Cites] FASEB J. 1996 Feb;10(2):258-66 [8641559.001]
  • [Cites] J Immunol. 1996 Sep 1;157(5):2168-73 [8757343.001]
  • [Cites] Nat Med. 1996 Sep;2(9):960-4 [8782444.001]
  • [Cites] FEBS Lett. 1996 Sep 9;393(1):105-8 [8804435.001]
  • [Cites] FEBS Lett. 1996 Oct 21;395(2-3):257-61 [8898107.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8116-20 [9223324.001]
  • [Cites] J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8 [9266987.001]
  • [Cites] J Virol. 1997 Nov;71(11):8531-41 [9343211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] Nat Med. 1998 May;4(5 Suppl):495-8 [9585194.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1247-59 [9593009.001]
  • [Cites] J Clin Invest. 1998 Jul 1;102(1):223-31 [9649576.001]
  • [Cites] J Virol. 1998 Nov;72(11):8952-60 [9765440.001]
  • [Cites] J Immunol Methods. 1998 Nov 1;220(1-2):129-38 [9839934.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2427-31 [9973525.001]
  • [Cites] J Hum Virol. 1998 May-Jun;1(4):282-92 [10195253.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1338-41 [10479168.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):666-77 [15688279.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):2185-9 [15699150.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1321-4 [15776379.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2802-11 [15591114.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8734-9 [15930136.001]
  • [Cites] J Virol. 2005 Aug;79(16):10200-9 [16051813.001]
  • [Cites] DNA Cell Biol. 2002 Sep;21(9):599-610 [12396602.001]
  • [Cites] Vaccine. 2002 Dec 19;20 Suppl 4:A61-5 [12477430.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1197-205 [12487826.001]
  • [Cites] J Virol. 2003 Aug;77(16):8607-20 [12885879.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6 [11172028.001]
  • [Cites] J Clin Virol. 2001 Apr;21(1):81-9 [11255101.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):553-61 [11350669.001]
  • [Cites] J Virol. 2001 Aug;75(15):6953-61 [11435575.001]
  • [Cites] Virus Res. 2002 Jan 30;82(1-2):91-101 [11885958.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2401-6 [14764710.001]
  • [Cites] Virology. 2005 Nov 10;342(1):1-12 [16109434.001]
  • [Cites] Diagn Microbiol Infect Dis. 2005 Nov;53(3):185-93 [16243475.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):53-67 [16343526.001]
  • [Cites] Virology. 2006 Sep 15;353(1):83-98 [16814356.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4028-36 [16951366.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7 [16940858.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2245-61 [17117011.001]
  • (PMID = 19265150.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / N01AI15431; United States / Intramural NIH HHS / / Z01 BC005536-21; United States / Intramural NIH HHS / / Z99 CA999999; United States / NIAID NIH HHS / AI / N01-AI-15431
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antiviral Agents; 0 / SAIDS Vaccines; 0 / Vaccines, DNA; 0 / env Gene Products, Human Immunodeficiency Virus; 0 / tat Gene Products, Human Immunodeficiency Virus
  • [Other-IDs] NLM/ NIHMS86377; NLM/ PMC2744397
  •  go-up   go-down


8. Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL: Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J Immunother; 2007 Jan;30(1):64-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recombinant interleukin-2 (rIL-2) is a pleiotropic cytokine that activates select immune effector cell responses associated with antitumor activity, including antibody-dependent cellular cytotoxicity (ADCC).
  • Rituximab is an anti-CD20 monoclonal antibody that activates ADCC in non-Hodgkin lymphoma (NHL).
  • Using in vitro killing assays, rIL-2 was shown to enhance activity of rituximab by activating ADCC and lymphokine-activated killer activity.
  • Additionally, the activity of rIL-2 plus rituximab F(ab')2 was similar to that of rIL-2 alone, indicating a critical role for immunoglobulin G1 Fc-FcgammaR-effector responses in mediating ADCC.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198084.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunoglobulin Fc Fragments; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


9. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T: Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci; 2010 May;101(5):1080-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
  • We then investigated whether killing of tumor cells harboring mutated KRAS can be improved by enhancing antibody-dependent cellular cytotoxicity (ADCC).
  • Protein- and glyco-engineering of antibodies' Fc region are established technologies to enhance ADCC by increasing antibodies' affinity to activating Fcgamma receptors.
  • Additionally, cells transfected with mutated KRAS were killed as effectively by ADCC as vector-transfected control cells.
  • Together, these data demonstrate that KRAS mutations are not sufficient to render tumor cells resistant to ADCC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331636.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FCGR3A protein, human; 0 / Immunoglobulin Fc Fragments; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, IgG; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


10. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol; 2005 Jan;128(2):192-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells cultured with IMiDs were examined in the presence or absence of anti-IL-2 antibody, ciclosporin A or depletion of CD56-positive cells.
  • IMiDs enhanced both NK cell cytotoxicity and ADCC induced by triggering IL-2 production from T cells.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638853.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P0-1 78378
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Immunologic Factors; 0 / Interleukin-2; 0 / NFATC Transcription Factors; 0 / Nuclear Proteins; 0 / Receptors, Interleukin-2; 0 / Transcription Factor AP-1; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


11. Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol; 2010 Dec;203(6):582.e1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sensitivity to MT201 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 4-hour chromium-release assays.
  • The effect of interleukin-2 on MT201 ADCC was also studied.
  • Although these cell lines were highly resistant to complement-dependent cytotoxicity and natural killer-dependent cytotoxicity in vitro (range of killing, 0-7%), EpCAM-positive cell lines showed high sensitivity to MT201 ADCC (range of killing, 27-66%).
  • CONCLUSION: MT201 may represent a novel, potentially highly effective treatment option for patients with ovarian carcinoma whose body is harboring disease refractory to chemotherapy.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1323-31 [17223740.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):483-8 [16678891.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):386-95 [17600130.001]
  • [Cites] Front Biosci. 2008;13:5195-201 [18508581.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):162-71 [19136966.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):860-6 [19574774.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5627-9 [19584271.001]
  • [Cites] Ann Oncol. 2010 Feb;21(2):275-82 [19633042.001]
  • [Cites] Urol Int. 2010;85(4):386-95 [20606402.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):482-7 [10821496.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):101-10 [12115595.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):341-8 [12819960.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6 [14508099.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4782-91 [14581349.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5818-24 [15313925.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(20):7893-7 [3094017.001]
  • [Cites] Cancer Invest. 1987;5(4):285-91 [2444316.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):123-32 [7678599.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2627-34 [7540106.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1337-48 [9382878.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1788-94 [9586892.001]
  • [Cites] Mol Immunol. 2006 Mar;43(8):1183-93 [16102830.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):417-23 [17211480.001]
  • (PMID = 20870202.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / P30 CA016359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / MT201 antibody, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS230505; NLM/ PMC2993821
  •  go-up   go-down


12. Beliard R, Waegemans T, Notelet D, Massad L, Dhainaut F, Romeuf Cd, Guemas E, Haazen W, Bourel D, Teillaud JL, Prost JF: A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol; 2008 Apr;141(1):109-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This mAb has been selected for its ability to strongly engage Fc-gamma receptor IIIA and to mediate a potent antibody-dependent cell cytotoxicity (ADCC) against RhD+ RBCs.
  • Thus, R297 is a promising candidate for the prevention of allo-immunization and represents a new generation of Fc-modified monoclonal antibodies with increased FcgammaRIII binding and increased ADCC.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279459.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / FCGR2A protein, human; 0 / FCGR3A protein, human; 0 / Immunoglobulin G; 0 / Isoantibodies; 0 / RHO(D) antibody; 0 / Receptors, IgG; 0 / Rho(D) Immune Globulin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


13. Kawaguchi Y, Kono K, Mizukami Y, Mimura K, Fujii H: Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res; 2009 Jun;29(6):2137-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme.
  • BACKGROUND: The escape mechanisms leading to trastuzumab-resistance are under investigation, but no report has yet described the mechanisms of escape from trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC).
  • In the present study, the mechanisms of escape from trastuzumab-mediated ADCC were elucidated using esophageal squamous cell carcinoma (SCC) cell clones.
  • MATERIALS AND METHODS: The esophageal SCC cell line TE4, which is highly susceptible to trastuzumab-mediated ADCC, was cloned by limited dilution, resulting in SCC clones with different sensitivities to trastuzumab-mediated ADCC.
  • RESULTS: There was no significant correlation between human epidermal growth factor receptor (HER) 2-expression on the tumor and the sensitivity to trastuzumab-mediated ADCC.
  • Altered major histocompatibility complex (MHC) class I expression treated by IFN-gamma or the blocking of natural killer (NK) cell inhibitory receptors did not induce significant changes in sensitivity to trastuzumab-mediated ADCC.
  • However, the tumor clones with a lower sensitivity to trastuzumab-mediated ADCC showed a reduced susceptibility to the perforin-granzyme system compared to those with a greater sensitivity to trastuzumab-mediated ADCC.
  • CONCLUSION: Lower susceptibility to the perforin-granzyme system is one of the important mechanisms explaining escape from trastuzumab-mediated ADCC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibody-Dependent Cell Cytotoxicity. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / immunology. Esophageal Neoplasms / immunology. Granzymes / metabolism. Perforin / metabolism


14. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K: Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol; 2007 May 4;368(3):767-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Removal of the fucose residue from the oligosaccharides attached to Asn297 of human immunoglobulin G1 (IgG1) results in a significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) via improved IgG1 binding to Fcgamma receptor IIIa.
  • These data suggest that the glycoform-dependent ADCC enhancement is attributed to a subtle conformational alteration in a limited region of IgG1-Fc.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Mol Biol. 2011 May 20;408(5):1001
  • (PMID = 17368483.001).
  • [ISSN] 0022-2836
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2DTQ/ 2DTS
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Immunoglobulin Fc Fragments; 0 / Immunoglobulin G; 0 / Solutions; 3713-31-3 / Fucose
  •  go-up   go-down


15. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Izawa S, Fujii H: NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus; 2010 Nov;23(8):675-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma.
  • In the present study, we analyzed NK cell dysfunction in patients with esophageal squamous cell carcinoma (ESCC), with a particular focus on the expression of CD16 and CD56 molecules.
  • Purified NK cells were evaluated for Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against epidermal growth factor receptor (EGFR)-expressing ESCC cell lines.
  • Although there were no significant differences in the distribution of CD56(dim) and CD56(bright) NK cells between ESCC patients and healthy donors, down-regulated CD16 and up-regulated CD56 were significantly observed on NK cells of ESCC patients, paralleling the impairment of Cetuximab-mediated ADCC, in comparison with healthy donors.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
  • (PMID = 20545975.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / Receptors, IgG; 0 / Transforming Growth Factor beta1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


16. Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R: A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J Immunol Methods; 2006 Aug 31;315(1-2):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals.
  • The cells pulsed with HIV-1 gp120 were then used as target cells for the measurement of antibody dependent cell mediated-cytotoxicity (ADCC) by flow cytometry.
  • Kinetic studies demonstrated that the sum of ADCC activity measured at 1-h and again at 2-h incubations by this flow cytometric method was comparable to the activity at 6 h by the standard chromium (51Cr) release assay (CRA).
  • ADCC activity of HIV-1 seropositive sera measured by this new technique correlated strongly with that of CRA (Pearson's correlation coefficient of 0.832; p-value < 0.001 and intraclass correlation coefficient of 0.903; p-value < 0.001).
  • The EGFP-CEM-NKr stable cell line provides a novel method to measure ADCC activity to HIV-1 gp120 by flow cytometry without pre-staining or pre-labeling target cells.


17. Xiong H, Li L, Liang QC, Bian HJ, Tang J, Zhang Q, Mi L, Chen ZN: Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent. Mol Med; 2006 Sep-Oct;12(9-10):229-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent.
  • The standard 51Cr release assay showed that like many other clinically validated IgG1 monoclonal antibodies, hCAb primarily acts by antibody-dependent cell-mediated cytotoxicity (ADCC).
  • The maximal cell lysis of ADCC induced by hCAb was over 50% in the presence of peripheral blood mononuclear cells (PBMCs).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1991 Jun 21;252(5013):1657-62 [2047874.001]
  • [Cites] Cancer Immunol Immunother. 1988;27(2):154-62 [3262013.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1397-403 [8622855.001]
  • [Cites] J Immunol Methods. 1997 May 12;204(1):77-87 [9202712.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4581-90 [9845524.001]
  • [Cites] BMC Cancer. 2004 Oct 15;4:75 [15488142.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):342-9 [15655555.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1514-22 [15735040.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):264-76 [15739250.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2327-36 [15788684.001]
  • [Cites] J Biochem Mol Biol. 2005 Jul 31;38(4):414-9 [16053708.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):66-73 [10561020.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):747-53 [10741693.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1991-9 [10864208.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2419-25 [11001893.001]
  • [Cites] Eur J Cancer. 2001 Jan;37 Suppl 1:S25-9 [11167088.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):341-8 [12819960.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):781-8 [14871799.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):292-302 [15120666.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1292-301 [15177487.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4699-707 [15383606.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1200-4 [15305184.001]
  • [Cites] Am J Clin Pathol. 1987 Oct;88(4):462-7 [3310608.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1992 Mar;14(2):91-3 [1618088.001]
  • (PMID = 17225871.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC1770013
  •  go-up   go-down


18. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol; 2008 Apr 10;26(11):1789-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The anti-HER-2/neu monoclonal antibody trastuzumab has been shown to engage both activatory (fragment C receptor [Fc gamma R]IIIa; Fc gamma RIIa) and inhibitory (Fc gamma RIIb) antibody receptors and Fc gamma R polymorphisms have been identified that may affect the antibody-dependent cell-mediated cytotoxicity (ADCC) of natural-killer cells/monocytes.
  • Trastuzumab-mediated ADCC of patients' peripheral blood mononuclear cells (PBMCs) was measured by chromium-51 release using a HER-2/neu-expressing human breast cancer cell line as a target.
  • The ADCC analysis showed that V/V and/or H/H PBMCs had a significantly higher trastuzumab-mediated cytotoxicity than PBMCs harboring different genotypes.
  • CONCLUSION: These data support for the first time the hypothesis that Fc gamma R-mediated ADCC plays an important role in the clinical effect of trastuzumab.


19. Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H: Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Aug;50(8):1361-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
  • Here we determined (i) the extent of antibody-dependent cellular cytotoxicity (ADCC) of four different mAbs against primary CLL cells, (ii) whether ADCC correlates with antigen density on CLL cells, and (iii) whether allogeneic natural killer (NK) cells display superior ADCC than autologous.
  • Effector cells for ADCC were (i) NK-92 cells not expressing FcR, (ii) NK-92 cells transfected with a high-affinity Fc receptor, (iii) autologous NK cells from patients with CLL, (iv) allogeneic NK cells.
  • Results suggest that ADCC contributes to killing of CLL cells by anti-CD20 antibodies (rituximab and veltuzumab), whereas mAbs against CD22 (epratuzumab) and CD23 (lumiliximab) showed minimal ADCC.
  • The magnitude of anti-CD20 mediated ADCC did not correlate with antigen density of CD20.
  • ADCC was not influenced by the FcR genotype expressed by autologous NK cells.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562616.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD22 protein, human; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Receptors, IgG; 0 / Recombinant Fusion Proteins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab; 0 / lumiliximab; 0 / veltuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B: Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization. Int J Oncol; 2009 Dec;35(6):1289-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vivo effector functions of rituximab include ADCC, CDC and seldom apoptosis.
  • Novel humanized anti-CD20 monoclonal antibodies were derived from a chimerized form of murine anti-CD20 1K11791, shown to exert a more potent ADCC, CDC and apoptotic activities compared to rituximab.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885551.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43 TW00013-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / NF-kappa B; 4F4X42SYQ6 / Rituximab; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


21. Olivier S, Jacoby M, Brillon C, Bouletreau S, Mollet T, Nerriere O, Angel A, Danet S, Souttou B, Guehenneux F, Gauthier L, Berthomé M, Vié H, Beltraminelli N, Mehtali M: EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs; 2010 Jul-Aug;2(4):405-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.
  • The experimental control of IgG fucosylation to enhance antibody dependent cell cytotoxicity (ADCC) activity constitutes one of the promising strategies to improve the efficacy of monoclonal antibodies and to potentially reduce the therapeutic cost.
  • Furthermore, mAbs produced on EB66 cells display a naturally reduced fucose content resulting in strongly enhanced ADCC activity.

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biotechnol. 2009 Feb 23;139(4):318-25 [19162096.001]
  • [Cites] Nat Rev Drug Discov. 2009 Mar;8(3):226-34 [19247305.001]
  • [Cites] Eur J Pharm Biopharm. 2010 Feb;74(2):127-38 [19853660.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4393-402 [20194898.001]
  • [Cites] Glycobiology. 2000 May;10(5):477-86 [10764836.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26733-40 [11986321.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3466-73 [12427744.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):455-9 [12571855.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6248-55 [15448014.001]
  • [Cites] Biochem Soc Symp. 1986;51:131-48 [3814165.001]
  • [Cites] Nat Biotechnol. 1999 Feb;17(2):176-80 [10052355.001]
  • [Cites] Nat Biotechnol. 2004 Nov;22(11):1393-8 [15529164.001]
  • [Cites] Appl Microbiol Biotechnol. 2005 Aug;68(3):283-91 [15834715.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7934-41 [16140965.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1159-69 [16127450.001]
  • [Cites] Nat Biotechnol. 2006 Feb;24(2):210-5 [16429149.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5032-6 [16330541.001]
  • [Cites] Biotechnol Bioeng. 2006 Jul 5;94(4):680-8 [16609957.001]
  • [Cites] Nat Biotechnol. 2006 Dec;24(12):1591-7 [17128273.001]
  • [Cites] Int Immunopharmacol. 2007 Jun;7(6):761-72 [17466910.001]
  • [Cites] Stem Cells Dev. 2007 Apr;16(2):213-22 [17521233.001]
  • [Cites] Biotechnol J. 2007 Jun;2(6):700-8 [17427997.001]
  • [Cites] J Biotechnol. 2007 Jun 30;130(3):300-10 [17559959.001]
  • [Cites] Curr Opin Biotechnol. 2007 Oct;18(5):387-92 [17951046.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):34-47 [18064051.001]
  • [Cites] BMC Biotechnol. 2007;7:84 [18047682.001]
  • [Cites] Front Biosci. 2008;13:4576-94 [18508530.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):471-8 [18606225.001]
  • [Cites] MAbs. 2009 May-Jun;1(3):230-6 [20065644.001]
  • (PMID = 20562528.001).
  • [ISSN] 1942-0870
  • [Journal-full-title] mAbs
  • [ISO-abbreviation] MAbs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 3713-31-3 / Fucose
  •  go-up   go-down


22. Shimodaira H, Komine K, Soeda H, Ishioka C: [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]. Gan To Kagaku Ryoho; 2010 May;37(5):795-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pre-clinical and clinical data indicated that antibody-dependent cellular cytotoxicity (ADCC) contributes to tumor cell lysis by anti-EGFR monoclonal antibodies.

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495309.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Receptors, IgG; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


23. Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, Stockmeyer B: Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol; 2007 Jul 1;179(1):337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The production of reactive oxygen intermediates (ROI) has been observed to occur during Ab-dependent, cell-mediated cytotoxicity (ADCC).
  • However, PMN from a patient with chronic granulomatous disease demonstrated strong ADCC against malignant lymphoma cells.
  • Furthermore, the inhibition of ROI production in PMN from healthy donors had no significant effect on ADCC.
  • Therefore, ROI production by the NADPH oxidase of PMN does not appear to be mandatory for PMN-mediated ADCC.
  • However, in our assays concanamycin A, an inhibitor of perforin-mediated ADCC by mononuclear cells, had no inhibitory effect on PMN-mediated ADCC.
  • The presence of transient PMN-tumor cell aggregates and the accumulation of PMN with tumor cell-derived membrane lipids and vice versa were associated with effective ADCC as measured by chromium-release or apoptosis induction.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579054.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / HLA-D Antigens; 0 / Macrolides; 0 / Membrane Glycoproteins; 0 / Membrane Lipids; 0 / Pore Forming Cytotoxic Proteins; 0 / Reactive Oxygen Species; 126465-35-8 / Perforin; 80890-47-7 / concanamycin A; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


24. Bonavida B: Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene; 2007 May 28;26(25):3629-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vivo mechanisms of rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell cytotoxicity (CDC), growth-inhibition and apoptosis.
  • These clones showed reduced expression of CD20 and hyperactivation of the above antiapoptotic signaling pathways and failure of rituximab to trigger the cells leading to inhibition of ADCC, CDC and chemo/immunosensitization.


25. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood; 2007 Oct 1;110(7):2561-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
  • We observed higher levels of FcgammaRIIIa transcripts among individuals with the FcgammaRIIIa-158 V/V versus V/F or F/F genotype (P < .001); increased cell surface CD16 expression by quantitative flow cytometry on NK cells from individuals expressing at least one valine at FcgammaRIIIa-158 versus F/F (P = .029); as well as augmented rituximab binding and rituximab-mediated, antibody-dependent cellular cytotoxicity (ADCC).
  • These results suggest that individuals expressing at least one valine at FcgammaRIIIa-158 might, in part, have better clinical outcomes due to increased CD16 expression, rituximab binding, and rituximab-mediated ADCC.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Oct 15;108(8):2648-54 [16825493.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):474-81 [15659493.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90 [17324336.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2253-64 [15073100.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6591-604 [11096108.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):455-9 [12571855.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6429-39 [8245476.001]
  • [Cites] J Immunol. 1996 Apr 15;156(8):2948-55 [8609432.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1109-14 [9242542.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1059-70 [9276722.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • (PMID = 17475906.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA087977; United States / NCI NIH HHS / CA / K23 CA087977-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1988936
  •  go-up   go-down


26. Hara H, Oyama T, Saku T: Fine needle aspiration cytology of basal cell adenoma of the salivary gland. Acta Cytol; 2007 Sep-Oct;51(5):685-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 5 items in 8 BCA and 22 non-BCA cases (adenoid cystic carcinoma [ADCC], basal cell adenocarcinoma, myoepithelioma, pleomorphic adenoma and polymorphous low-grade adenocarcinoma) that displayed mimicking cytology were examined cytologically.
  • RESULTS: The useful items were < 5.1 microm in mean of epithelial nuclear short diameter; mild atypia on definitive diagnosis; stromal cell cluster combining smooth margin surrounding the epithelial cell cluster or containing the epithelial cell cluster; epithelial clusters surrounded by or adhered to a thick, hyalinized smooth margin without stromal cluster; and closely fastened, tight clusters with denser cytoplasm than ADCC, but an indistinct border, with oval nuclei and no hyaline cells.
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Epithelium / pathology. Epithelium / ultrastructure. Humans. Immunohistochemistry. Myoepithelioma / pathology. Organelle Size. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910337.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Lin TS: Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med; 2010;3:51-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC).
  • Patients with the high-affinity FCGR3a 158 V/V polymorphism may be more likely to respond to therapy, if ADCC is the primary in vivo mechanism of action of ofatumumab.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):362-71 [16785532.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5486-95 [18390837.001]
  • [Cites] J Immunol. 2009 Jul 1;183(1):749-58 [19535640.001]
  • [Cites] Med Oncol. 2010 Sep;27(3):743-6 [19662541.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1749-55 [20194866.001]
  • (PMID = 23226042.001).
  • [ISSN] 1178-7066
  • [Journal-full-title] Pharmacogenomics and personalized medicine
  • [ISO-abbreviation] Pharmgenomics Pers Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3513208
  • [Keywords] NOTNLM ; CD20 / CLL / NHL / lymphoma / monoclonal antibody
  •  go-up   go-down


28. Liu M, Ke T, Wang Z, Yang Q, Chang W, Jiang F, Tang Z, Li H, Ren X, Wang X, Wang T, Li Q, Yang J, Liu J, Wang QK: Identification of a CRYAB mutation associated with autosomal dominant posterior polar cataract in a Chinese family. Invest Ophthalmol Vis Sci; 2006 Aug;47(8):3461-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Linkage analysis was performed with a panel of microsatellite markers flanking candidate genetic loci for cataracts, including 14 known autosomal dominant congenital cataract (ADCC) genes.


29. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K: Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol; 2007 May;44(12):3122-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC) is considered to be an important therapeutic function for clinical efficacy of monoclonal antibodies.
  • Recent studies have revealed two methods to increase binding affinity for FcgammaRIIIa and enhance ADCC more efficiently for antibodies: (i) fucose removal from antibody N-linked complex oligosaccharides and (ii) amino acid mutations in the antibody Fc region.
  • In this study, we compare the biological activities of the methods of generating high ADCC antibodies.
  • We used a fucose-negative antibody and two antibodies with sets of mutations, demonstrated previously to optimally enhance ADCC using the chimeric anti-CD20 antibody, rituximab, as the model.
  • Despite the differences manifested in binding for the FcgammaR, ADCCs were indistinguishable between methods and even when the methods were combined.
  • These results indicate that the affinity of binding to FcgammaRIIIa does not predict ADCC beyond a certain threshold and that each method alone is sufficient to induce maximal ADCC of the antibody.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379311.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 3713-31-3 / Fucose
  •  go-up   go-down


30. Thejass P, Kuttan G: Augmentation of natural killer cell and antibody-dependent cellular cytotoxicity in BALB/c mice by sulforaphane, a naturally occurring isothiocyanate from broccoli through enhanced production of cytokines IL-2 and IFN-gamma. Immunopharmacol Immunotoxicol; 2006;28(3):443-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC) also was enhanced significantly in both normal as well as tumor-bearing animals after sulforaphane administration compared with untreated control tumor-bearing animals.
  • [MeSH-major] Antibody-Dependent Cell Cytotoxicity / drug effects. Brassica / chemistry. Carcinoma, Ehrlich Tumor / drug therapy. Killer Cells, Natural / drug effects. Thiocyanates / pharmacology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997793.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Isothiocyanates; 0 / Mitogens; 0 / Plant Extracts; 0 / Thiocyanates; 3129-90-6 / isothiocyanic acid; 4478-93-7 / sulforafan; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


31. Baumann BC, Stussi G, Huggel K, Rieben R, Seebach JD: Reactivity of human natural antibodies to endothelial cells from Galalpha(1,3)Gal-deficient pigs. Transplantation; 2007 Jan 27;83(2):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro, IgG NAb induce human natural killer (NK) cell-mediated lysis of pEC by antibody-dependent cell-mediated cytotoxicity (ADCC).
  • ADCC was analyzed by chromium-release assays using human serum and freshly isolated NK cells.
  • NAb/complement-induced lysis and ADCC of Gal-deficient compared to Gal-positive pEC were 21% and 29%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264816.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antibodies; 0 / Disaccharides; 13168-24-6 / galactosyl-(1-3)galactose
  •  go-up   go-down


32. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Fujii H: Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer; 2010 Feb 2;102(3):520-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.
  • BACKGROUND: We previously reported that Trastuzumab- and Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in cancer patients was impaired in comparison with that in healthy donors because of NK-cell dysfunction.
  • In this study, we evaluated whether IL-21 could improve the impairment of ADCC in patients with oesophageal squamous cell carcinoma (ESCC), as IL-21 was reported to have the ability to activate NK cells.
  • METHODS: We examined Trastuzumab- and Cetuximab-mediated ADCC of peripheral blood mononuclear cells (PBMCs) or of enriched NK cells derived from ESCC patients (n=20) and healthy donors (n=16) in the presence of IL-21.
  • We further analysed ADCC-related molecules (perforin, granzyme-B, and CD247) on NK cells in response to IL-21.
  • RESULTS: Trastuzumab- and Cetuximab-mediated ADCC of PBMCs or of enriched NK cells was enhanced by the addition of IL-21 in a dose-dependent manner and the levels of ADCC enhanced by IL-21 in patients were high enough in comparison with those in healthy donors, paralleling the upregulation of CD247 on NK cells.
  • CONCLUSION: IL-21 could efficiently restore impaired ADCC in ESCC patients with the upregulation of CD247 molecules.
  • [MeSH-major] Antibody-Dependent Cell Cytotoxicity / drug effects. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Interleukins / pharmacology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1985 Feb 16;1(8425):366-8 [2857420.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1059-70 [9276722.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):96-100 [9288975.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 [10482195.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1253-60 [15785739.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4898-904 [16000588.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1173-80 [16161046.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):120-9 [16785506.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5006-13 [17015683.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):781-7 [17096332.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2827-34 [17312126.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3630-6 [17575227.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):480-3 [17581589.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):494-501 [17622245.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6419-28 [17962339.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11991-9 [18089830.001]
  • [Cites] Immunology. 2008 Apr;123(4):575-83 [18005035.001]
  • [Cites] Nat Rev Drug Discov. 2008 Mar;7(3):231-40 [18259184.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2034-9 [18347008.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(1):12-8 [19042123.001]
  • [Cites] Inflamm Bowel Dis. 2009 Aug;15(8):1133-44 [19322899.001]
  • [Cites] Cell Immunol. 1999 Dec 15;198(2):103-10 [10648124.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):57-63 [11081504.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4892-900 [11406568.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):1-5 [11418623.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5813-7 [12384543.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):895-904 [15143334.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):795-804 [8039107.001]
  • (PMID = 20029417.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Interleukins; 0 / Receptors, Interleukin-21; 0 / interleukin-21; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2822939
  •  go-up   go-down


33. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M: Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res; 2006 May 1;12(9):2879-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recent studies have revealed that fucosylated therapeutic IgG1s need high concentrations to compensate for FcgammaRIIIa-competitive inhibition of antibody-dependent cellular cytotoxicity (ADCC) by endogenous human plasma IgG.
  • Here, we investigated whether ADCC of nonfucosylated therapeutic IgG1 is also influenced by plasma IgG in the same way as fucosylated IgG1s.
  • EXPERIMENTAL DESIGN: Ex vivo ADCC upon CD20+ human B cells was induced by incubation of human whole blood with nonfucosylated and/or fucosylated anti-CD20 IgG1s rituximab, and quantified by measuring the remaining CD19+ human B cells using flow cytometry.
  • In contrast, nonfucosylated anti-CD20 reached saturated ADCC at lower concentrations (0.01-0.1 microg/mL) with much higher efficacy than fucosylated anti-CD20 in all nine donors through improved FcgammaRIIIa binding.
  • CONCLUSIONS: Our data showed that nonfucosylated IgG1, not including fucosylated counterparts, can evade the inhibitory effect of plasma IgG on ADCC through its high FcgammaRIIIa binding.
  • Hence, nonfucosylated IgG1 exhibits strong therapeutic potential through dramatically enhanced ADCC at low doses in humans in vivo.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675584.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / FCGR3A protein, human; 0 / Immunoglobulin G; 0 / Receptors, IgG; 3713-31-3 / Fucose; 4F4X42SYQ6 / Rituximab; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


34. Kim JS, Nag P, Landay AL, Alves M, Cohn MH, Bremer JW, Baum LL: Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. FEMS Immunol Med Microbiol; 2006 Nov;48(2):267-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiviral substances in saliva responsible for this may include HIV-1-specific antibody-dependent cell-mediated cytotoxicity (ADCC).
  • We evaluated saliva ADCC titers of 62 HIV-1-infected women from the Women's Interagency HIV Study (WIHS) and 55 uninfected individuals.
  • HIV-1-infected women were less likely to have ADCC activity in saliva than in serum or cervical lavage fluid (CVL).
  • 24% of HIV-1-positive women and a similar percentage of uninfected women had HIV-1-specific saliva ADCC activity.
  • A significant amount of saliva ADCC activity in infected women was HIV-gp120-specific.
  • These studies demonstrate that HIV-specific ADCC activity can be present in saliva.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Women and HIV .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978244.001).
  • [ISSN] 0928-8244
  • [Journal-full-title] FEMS immunology and medical microbiology
  • [ISO-abbreviation] FEMS Immunol. Med. Microbiol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD40539; United States / NIAID NIH HHS / AI / U01-AI-34993
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HIV Antibodies; 0 / HIV Envelope Protein gp120; 0 / Immunoglobulin A
  •  go-up   go-down


35. Karakas Z, Tugcu D, Unuvar A, Atay D, Akcay A, Gedik H, Kayserili H, Dogan O, Anak S, Devecioglu O: Li-Fraumeni syndrome in a Turkish family. Pediatr Hematol Oncol; 2010 May;27(4):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Li-Fraumeni syndrome (LFS) is one of the familial cancers characterized by different tumors and hereditary TP53 mutations.
  • The adrenocortical carcinoma (ACC) association with acute leukemia is unusual in childhood, even in LFS.
  • The authors here present a family with pR337P mutation in TP53 gene who had a child with acute lymphoblastic leukemia (ALL) and associated adrenocortical carcinoma as a case 1 and his cousin with brain tumor as a case 2.
  • A hereditary TP53 mutation supported the diagnosis of LFS in this family.
  • [MeSH-major] Adrenocortical Carcinoma / genetics. Brain Neoplasms / genetics. Li-Fraumeni Syndrome / genetics. Mutation, Missense. Neoplasms, Second Primary / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426520.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


36. Yang L, Jiang H, Shi B, Wang H, Li J, Wang H, Yao M, Li Z: Identification and characterization of Ch806 mimotopes. Cancer Immunol Immunother; 2010 Oct;59(10):1481-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, in an antibody-dependent cellular cytotoxicity assay (ADCC), the mimotope-induced antibodies specifically lysed human Huh-7-EGFRvIII cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544195.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / SCGB1A1 protein, human; 0 / Scgb1a1 protein, mouse; 0 / monoclonal antibody 806; 9060-09-7 / Uteroglobin
  •  go-up   go-down


37. Schaedel O, Reiter Y: Antibodies and their fragments as anti-cancer agents. Curr Pharm Des; 2006;12(3):363-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon binding to the Fc Receptor on effector cells, the crystallisable fragment (Fc) region elicits the onslaught of Antigen Dependent Cell-mediated Cytotoxicity (ADCC) and the plasma-native Complement Dependent Cytotoxicity (CDC) response and apoptosis.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454750.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Recombinant Proteins
  • [Number-of-references] 212
  •  go-up   go-down


38. Szabó D, Zsippai A, Bendes M, Tömböl Z, Szabó PM, Rácz K, Igaz P: [Pathogenesis of adrenocortical cancer]. Orv Hetil; 2010 Jul 18;151(29):1163-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathogenesis of adrenocortical cancer].
  • [Transliterated title] A mellékvesekéreg-carcinoma molekuláris patogenezise.
  • Adrenocortical cancer is a rare tumor with poor prognosis.
  • Whereas most cases occur in a sporadic setting, there are very rare hereditary forms that are important for the understanding of tumor pathogenesis.
  • The hereditary syndromes associated with adrenocortical cancer are: Li-Fraumeni's syndrome, Beckwith-Wiedemann's syndrome and familial adenomatous polyposis, whereas multiple endocrine neoplasia type 1, Carney's complex and McCune-Albright's syndrome mostly predispose to benign adrenocortical tumors.
  • Options for medical treatment of adrenocortical cancer are rather limited.
  • In this study, the pathogenesis of hereditary tumor syndromes, the alterations in sporadic tumors and the most recent molecular-bioinformatical observations are discussed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591784.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Wnt Proteins; 0 / beta Catenin; 67763-97-7 / Insulin-Like Growth Factor II
  • [Number-of-references] 37
  •  go-up   go-down


39. Gille C, Spring B, Tewes LJ, Löffler J, Dannecker GE, Hoffmann MK, Eichner M, Poets CF, Orlikowsky TW: Diminished response to interleukin-10 and reduced antibody-dependent cellular cytotoxicity of cord blood monocyte-derived macrophages. Pediatr Res; 2006 Aug;60(2):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A helper MPhi-type (Mh-MPhi) is induced by interferon gamma (IFN-gamma), whereas a cytotoxic MPhi-type (Mc-MPhi), induced by interleukin-10 (IL-10), is a potent mediator of antibody-dependent cellular cytotoxicity (ADCC).
  • CBMPhi or PBMPhi were co-cultured with MPhi-depleted mononuclear cells of adults and CD4-targeting antibodies as models for ADCC were added.
  • IL-10 failed to enhance their ADCC capacity, which was in contrast to PBMPhi (p < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864695.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / HLA-DR Antigens; 0 / Mitogens; 0 / RNA, Messenger; 0 / Receptors, IgG; 130068-27-8 / Interleukin-10
  •  go-up   go-down


40. Ranft K, Thepen T, Fischer R, Barth S, Stöcker M: Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells. Cancer Lett; 2009 Sep 18;282(2):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The elimination of lymphoma cells was preferentially achieved by phagocytosis, not through the ADCC pathway additionally activated by the chemically-linked molecule.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345477.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, CD30; 0 / Immunoglobulin Fragments; 0 / Receptors, IgG; 0 / Recombinant Proteins; 0 / immunoglobulin Fv
  •  go-up   go-down


41. Si N, Sun M, Lu CX, Liu YS, Qi Z, Yang W, Zhao XL, Zhang X: [Identification of a novel TP53 germline mutation in one child with adrenocortical carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 May 26;89(20):1402-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of a novel TP53 germline mutation in one child with adrenocortical carcinoma].
  • OBJECTIVE: To detect the germline TP53 gene mutation in a child with pediatric adrenocortical carcinoma (ADCC) in order to provide genetic diagnosis and counseling.
  • METHODS: Genomic DNA was extracted from peripheral blood from a girl with ADCC and her parents.
  • CONCLUSION: A novel germline mutation in the TP53 gene has been identified in one case with pediatric ADCC.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Genes, p53. Germ-Line Mutation

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671334.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC: The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol; 2009 Mar;144(6):848-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SGN-40 also mediated antibody-dependent cellular cytotoxicity (ADCC) predominantly through natural killer (NK) cells.
  • We therefore examined for the combinatorial effect of lenalidomide and SGN-40 and demonstrated that both enhanced direct apoptosis and ADCC against primary CLL B cells.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5180-9 [18772452.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] Br J Haematol. 2003 May;121(4):592-6 [12752100.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2846-52 [15087402.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2239-45 [15512812.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2449-56 [1702326.001]
  • [Cites] Annu Rev Immunol. 1994;12:881-922 [7516669.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2597-603 [7522634.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 1997 May;97(2):409-17 [9163608.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):478-83 [9716030.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11712-20 [16357183.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2569-77 [17440052.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2561-4 [17475906.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Blood. 2008 Aug 1;112(3):711-20 [18497318.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • (PMID = 19183192.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / T-32-5CA009338; United States / NCI NIH HHS / CA / P01 CA095426-06; United States / NCI NIH HHS / CA / P01 CA81534-02; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / CA095426-06; United States / NCI NIH HHS / CA / T32 CA009338
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD40; 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ NIHMS139967; NLM/ PMC2776067
  •  go-up   go-down


43. Huang J, Shibaguchi H, Zhao J, Luo N, Kuroki M, Kinugasa T, Hirose Y, Yamada H, Kuroki M: IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer Res; 2006 Mar-Apr;26(2A):1057-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The IgG isotype of antibodies is very important for their biological functions such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
  • RESULTS: The converted C2-45 (cIgG1) retained the original antigen-binding activity and showed significantly higher CDC and ADCC activities against CEA-expressing tumor cells than did the original C2-45 (IgG4).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carcinoembryonic Antigen; 0 / Immunoglobulin G; 0 / Recombinant Proteins; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


44. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E: High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother; 2005 Jul;54(7):677-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This antibody mediates antibody-dependent cellular cytotoxicity (ADCC) and has already been used for anti-idiotype therapy trials.
  • These anti-mimotope antibodies were capable of inducing specific lysis of 518A2 melanoma cells in ADCC assays with murine effector cells.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565329.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Albumins; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HMW-MAA; 0 / Peptide Fragments; 0 / Peptide Library; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


45. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun; 2007;7:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, MORAb-003 elicited robust antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro, and inhibited growth of human ovarian tumor xenografts in nude mice.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2000 Jan;113 Pt 2:349-57 [10633085.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:86-96 [16382047.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):106-14 [11279613.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Sep;128(9):484-92 [12242512.001]
  • [Cites] Gene Ther. 2003 Jun;10(12):1018-25 [12776159.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1058-66 [14871838.001]
  • [Cites] Int J Cancer. 1985 Apr 15;35(4):469-75 [2580800.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):297-303 [2434438.001]
  • [Cites] Biochim Biophys Acta. 1987 Jul 16;925(1):36-47 [3474029.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(1):15-25 [2007534.001]
  • [Cites] Eur J Cancer. 1991;27(6):724-9 [1829912.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5329-38 [1717147.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6006-9 [1631087.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):2000-5 [1432162.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):557-67 [8434649.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5413-8 [8221680.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5791-6 [8242637.001]
  • [Cites] Eur J Cancer. 1994;30A(3):363-9 [8204360.001]
  • [Cites] Int J Cancer. 1995 Apr 21;64(2):92-8 [7615359.001]
  • [Cites] Int J Cancer. 1997 Apr 22;74(2):193-8 [9133455.001]
  • [Cites] J Cell Biochem. 1997 Jun 15;65(4):479-91 [9178098.001]
  • [Cites] Br J Cancer. 1997;76(1):77-82 [9218736.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2712-20 [9406729.001]
  • [Cites] Eur J Nucl Med. 1998 Nov;25(11):1552-61 [9799353.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1168-76 [10914906.001]
  • (PMID = 17346028.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / LK26 antigen; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ PMC2935753
  •  go-up   go-down


46. Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H: Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci; 2008 Dec;99(12):2461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
  • A murine (mAHM) and a humanized (AHM) monoclonal antibody against CD317 (also called tetherin, BST2, or HM1.24 antigen), expressed preferentially in neoplastic B cells such as multiple myeloma, exhibited antitumor effects as a result of antibody-dependent cellular cytotoxicity (ADCC).
  • The putative interferon (IFN) response elements IRF-1/2 and ISGF3 are present in the promoter of the CD317 gene, and IFN has been used for the treatment of not only myeloproliferative diseases but also solid tumors such as renal cell carcinoma (RCC) and melanoma.
  • Flow cytometry and in vitro ADCC assays with human or mouse effector cells demonstrated that IFN-alpha markedly increased the amount of cell surface CD317 and augmented the ADCC activity of mAHM and AHM in RCC cells and to a lesser extent in melanoma cells.
  • [MeSH-major] Antibodies, Anti-Idiotypic / pharmacology. Antigens, CD / immunology. Carcinoma, Renal Cell / therapy. Interferon-alpha / pharmacology. Kidney Neoplasms / therapy. Membrane Glycoproteins / immunology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032371.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / BST2 protein, human; 0 / Fluorescent Dyes; 0 / GPI-Linked Proteins; 0 / Interferon-alpha; 0 / Membrane Glycoproteins; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


47. Wuhrer M, Porcelijn L, Kapur R, Koeleman CA, Deelder A, de Haas M, Vidarsson G: Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res; 2009 Feb;8(2):450-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various biological activities of immunoglobulin G (IgG) including antibody-dependent cellular cytotoxicity (ADCC) are modulated by the structural features of the N-glycans in the Fc part.
  • Because IgG1 Fc-core-fucosylation is known to influence ADCC activity, modulation of core-fucosylation may have a profound effect on disease severity and prognosis.

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942870.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Human Platelet; 0 / Immunoglobulin G; 0 / Immunologic Factors; 0 / Isoantibodies
  •  go-up   go-down


48. Epivatianos A, Iordanides S, Zaraboukas T, Antoniades D: Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies. Oral Dis; 2005 May;11(3):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies.
  • OBJECTIVE: The purpose of this study was to investigate immunohistochemically the expression of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in adenoid cystic carcinoma (AdCC) and polymorphous low-grade adenocarcinoma (PLGA) in an attempt to assess the ability of these markers to distinguish AdCC from PLGA when the histological features on routine hematoxylin and eosin are equivocal.
  • MATERIALS AND METHODS: Fourteen specimens of AdCC, 10 PLGA, and five normal minor salivary glands fixed in 10% formalin and embedded in paraffin, were retrieved from the files of our department and were retrospectively studied with the streptavidin-biotin complex method using the epithelial membrane and carcinoembryonic antibodies.
  • RESULTS: The immunoreactivities and the expression patterns of EMA and CEA in AdCC and PLGA were similar.
  • CONCLUSIONS: The results of this study suggest that the immunostaining of AdCC and PLGA with EMA and CEA could not offer an adjunctive aid in differential diagnosis between these two tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Salivary Gland Neoplasms / diagnosis


49. Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, Chen S, Liu J, Kuhne MR, Srinivasan M, Assad A, Witte A, Graziano RF, King DJ: In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res; 2009 May 15;15(10):3376-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Assays measuring antibody binding to CD30-expressing cells and FcgammaRIIIa (CD16) transfectants as well as antibody-dependent cellular cytotoxicity (ADCC) were conducted.
  • MDX-1401 greatly improved ADCC activity as evidenced by a decrease in half-maximal effective concentration (EC(50)) and an increase in maximum cell lysis when compared with MDX-060.
  • Increased ADCC activity was observed among a panel of cell lines, including one with very low CD30 antigen expression in which parental antibody failed to induce any detectable ADCC.
  • CONCLUSIONS: The low doses of antibody required for ADCC activity irrespective of donor genotype, the ability to mediate ADCC in target cells expressing low levels of CD30, and increased in vivo efficacy support the development of MDX-1401 for treatment of malignant lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401346.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Carbohydrates; 0 / FCGR3A protein, human; 0 / MDX-1401; 0 / Receptors, IgG; 3713-31-3 / Fucose
  •  go-up   go-down


50. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther; 2007 Jul;6(7):2065-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the role of antibody-dependent cellular cytotoxicity (ADCC) using JIMT-1 cells that are ErbB2 positive but intrinsically resistant to trastuzumab in vitro.
  • The effect is likely to be mediated via ADCC because trastuzumab-F(ab')(2) was ineffective in this model.
  • Moreover, in vitro ADCC reaction of human leukocytes was equally strong against breast cancer cells intrinsically sensitive (SKBR-3) or resistant (JIMT-1) to trastuzumab or even against a subline of JIMT-1 that was established from xenograft tumors growing despite trastuzumab treatment.
  • These results suggest that ADCC may be the predominant mechanism of trastuzumab action on submacroscopic tumor spread.
  • Thus, measuring the ADCC activity of patient's leukocytes against the tumor cells may be a relevant predictor of clinical trastuzumab responsiveness in vivo.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620435.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


51. Iannello A, Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev; 2005 Dec;24(4):487-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, several in vitro and in vivo studies have demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) is their predominant mode of action against cancer cells.
  • Several strategies are proposed to potentiate the mAb-mediated ADCC in cancer patients.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408158.001).
  • [ISSN] 0167-7659
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 80
  •  go-up   go-down


52. Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frödin JE: Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol; 2005 Jun;26(6):1581-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
  • The EpCAM antigen is highly expressed on colorectal carcinoma (CRC) cells.
  • The chimeric variant of anti-EpCAM MAb (anti-EpCAM cMAb) interacts more efficiently with human effector cells (ADCC) than the murine counterpart in the killing of colorectal carcinoma cells in vitro, an important mechanism of action for antibody in vivo.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870873.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Recombinant Fusion Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


53. Kim TJ, Kim N, Kim EO, Choi JR, Bluestone JA, Lee KM: Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology; 2010 Aug;130(4):545-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Natural killer (NK) cells can destroy xenogeneic tissues by antibody-dependent cell cytotoxicity (ADCC) and direct lysis.
  • Unlike ADCC, activating interactions between human NK receptors and their cognate ligands in pigs are not fully elucidated.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Transplant. 2005 Sep;5(9):2085-93 [16095487.001]
  • [Cites] Nat Med. 2009 Jul;15(7):746-9 [19584865.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5463-70 [16210654.001]
  • [Cites] Exp Hematol. 2005 Oct;33(10):1160-71 [16219538.001]
  • [Cites] Blood. 2006 Feb 1;107(3):994-1002 [16204312.001]
  • [Cites] Nat Med. 2006 Mar;12(3):301-3 [16491083.001]
  • [Cites] Nat Med. 2006 Mar;12(3):304-6 [16501570.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3312-4 [17175258.001]
  • [Cites] Transplantation. 2007 Feb 15;83(3):323-32 [17297407.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2181-90 [10979964.001]
  • [Cites] Nat Immunol. 2000 Nov;1(5):419-25 [11062502.001]
  • [Cites] Annu Rev Med. 2002;53:133-47 [11818467.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1089-92 [11778012.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):251-5 [11875425.001]
  • [Cites] Transplantation. 2002 Mar 15;73(5):789-96 [11907429.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 3;309(4):992-8 [13679072.001]
  • [Cites] Lab Anim Care. 1968 Feb;18(1):104-9 [4230573.001]
  • [Cites] Nature. 1986 Feb 20-26;319(6055):675-8 [3951539.001]
  • [Cites] Biochem Biophys Res Commun. 1988 May 31;153(1):46-50 [3288207.001]
  • [Cites] Science. 1995 Apr 21;268(5209):405-8 [7716543.001]
  • [Cites] Transpl Immunol. 1996 Dec;4(4):293-9 [8972559.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3148-54 [9120268.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):111-20 [9212737.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3655-61 [9317166.001]
  • [Cites] Transplantation. 1998 Mar 15;65(5):727-34 [9521210.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2065-72 [9625766.001]
  • [Cites] J Exp Med. 1998 Oct 5;188(7):1267-75 [9763606.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6648-56 [9862693.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] J Immunol Methods. 2004 Nov;294(1-2):15-22 [15604012.001]
  • [Cites] Mol Immunol. 2005 Feb;42(4):489-94 [15607804.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2653-60 [15728472.001]
  • [Cites] Mol Immunol. 2005 Apr;42(6):665-71 [15781110.001]
  • [Cites] Xenotransplantation. 2005 May;12(3):181-8 [15807768.001]
  • [Cites] Mol Immunol. 2005 Jun;42(10):1205-14 [15829309.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):213-8 [15972651.001]
  • [Cites] Transpl Int. 2005 May;17(12):787-94 [15711982.001]
  • [Cites] Xenotransplantation. 2007 Mar;14(2):126-34 [17381687.001]
  • [Cites] Nat Rev Immunol. 2007 Jul;7(7):519-31 [17571072.001]
  • [Cites] Nat Immunol. 2008 May;9(5):495-502 [18425106.001]
  • [Cites] Nat Immunol. 2008 May;9(5):503-10 [18425107.001]
  • [Cites] Mol Immunol. 2008 Jul;45(12):3354-62 [18533264.001]
  • [Cites] Am J Transplant. 2008 Oct;8(10):1972-81 [18828764.001]
  • [Cites] Transplantation. 2009 Jan 15;87(1):35-43 [19136889.001]
  • [Cites] Xenotransplantation. 2009 Jan-Feb;16(1):19-26 [19243557.001]
  • [Cites] Exp Mol Med. 2009 Mar 31;41(3):161-70 [19293635.001]
  • [Cites] Cell Cycle. 2009 Apr 15;8(8):1168-75 [19282669.001]
  • [Cites] J Immunol. 2009 Jun 1;182(11):6933-42 [19454690.001]
  • [Cites] Cell Biol Int. 2005 Aug;29(8):638-46 [15950500.001]
  • (PMID = 20406306.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Heterophile; 0 / Antibodies, Monoclonal; 0 / Antigens, CD2; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Organic Chemicals; 0 / PD 98058; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2913265
  •  go-up   go-down


54. Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, Jung G, Martin D, Niethammer D, Lang P: Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant; 2005 Jul;36(2):91-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the ability of rituximab to mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) with effector cells and complement from patients who were transplanted with T-cell-depleted grafts from unrelated or mismatched related donors.
  • Highest lytic activity (ADCC) was observed against leukemia-derived MHH4 cells and Burkitt's lymphoma-derived Raji cells in the first months after transplantation, corresponding to the high percentage of regenerating CD56+ CD16+ cells.
  • Combination of ADCC and CDC had additive effects.

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908973.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


55. Sung JS, Park KH, Kim YH: Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. Cancer Genet Cytogenet; 2010 Apr 1;198(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used aCGH to compare genomic alterations in fresh-frozen lung cancer tissues of 21 adenocarcinomas (AdCCs) (11 early relapse and 10 nonrelapse) and identified genomic alterations that showed significant by different frequency between early relapse and nonrelapse AdCCs.
  • To further confirm the results of aCGH, copy number changes of cancer-related candidate genes in AdCC patients were compared by real-time quantitative polymerase chain reaction.
  • Genomic alterations of chromosome 11p region in AdCC patients were observed with aCGH, and a relapsable marker was identified in the nonrelapse group.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303011.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


56. Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A, Lo KM: An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood; 2005 May 15;105(10):3972-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The resulting immunocytokine, DI-Leu16-IL-2, retained full anti-CD20 activity as assessed by fluorescence-activated cell-sorting (FACS) analysis, and had enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function relative to the DI-Leu16 antibody or control anti-CD20 antibody (rituximab).
  • Antitumor activity of DI-Leu16-IL-2 was shown to partially but not entirely depend on Fc receptor (R) binding, suggesting that ADCC and targeting of IL-2 both play roles in the mechanism of tumor clearance.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692062.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


57. Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM: Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma; 2010 Jul;51(7):1241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) might enhance the efficacy of rituximab by augmenting antibody-dependent cellular cytotoxicity (ADCC).

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496994.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA116471; United States / NCI NIH HHS / CA / K23CA133196; United States / NCI NIH HHS / CA / K24CA116471
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


58. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S: Cetuximab: from bench to bedside. Curr Cancer Drug Targets; 2010 Feb;10(1):80-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cetuximab is also able to display cytotoxic effect through antibody-dependent cellular cytotoxicity (ADCC).
  • Moreover, numerous clinical trials demonstrated cetuximab efficacy in different tumor types and it is approved by Food and Drugs Administration (FDA) for use in the treatment of metastatic colorectal cancer (mCRC) as single agent or in combination with chemotherapy, for locally/regionally advanced head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy, and as monotherapy for recurrent/metastatic HNSCC after failing platinum-based chemotherapy.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Squamous Cell / drug therapy. Cetuximab. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Drug Resistance, Neoplasm / drug effects. Head and Neck Neoplasms / drug therapy. Humans. Matrix Metalloproteinase Inhibitors. Mice

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088790.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 154
  •  go-up   go-down


59. Bonavida B, Vega MI: Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist Updat; 2005 Feb-Apr;8(1-2):27-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vivo mechanism by which rituximab mediates its effects is not clear, though ADCC, CDC and apoptosis have been suggested and supported by several studies.


60. Shimizu M, Imai M: Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro. Biol Pharm Bull; 2008 Dec;31(12):2288-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
  • Using oral squamous cell carcinoma cell lines, we demonstrate here that tumor-specific targeting of MUC1 with the specific monoclonal antibody C595 has functional consequences with regard to complement deposition on MUC1-expressing oral cancer cell lines.
  • Anti-MUC1 monoclonal antibody (mAb) also induced complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to OSCC cells, and these effects were strongly correlated with MUC1 expression.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Carcinoma, Squamous Cell / drug therapy. Immunotherapy. Mouth Neoplasms / drug therapy. Mucin-1 / immunology


61. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol; 2005 Feb 15;174(4):2185-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effector cells armed with Abs can eliminate virus-infected target cells by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that has been largely overlooked in HIV vaccine development.
  • Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC activity correlating with protection against SIV in rhesus macaques (Macacca mulatta).
  • Priming with replicating adenovirus type 5 host range mutant-SIV recombinants, followed by boosting with SIV gp120, elicited Abs with ADCC activity against SIV(mac251)-infected cells.
  • In vitro ADCC activity correlated with in vivo reduced acute viremia after a mucosal challenge with pathogenic SIV.
  • Our findings expose ADCC activity as an immune correlate that may be relevant in the rational design of an efficacious vaccine against HIV.

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699150.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, env; 0 / Immunoglobulin G; 0 / SAIDS Vaccines; 0 / Vaccines, Synthetic
  •  go-up   go-down


62. Zhang LY, Yam GH, Tam PO, Lai RY, Lam DS, Pang CP, Fan DS: An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. Mol Vis; 2009;15:1127-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A heterozygous missense substitution, c.34C>T, in CRYAA, which is responsible for the R12C amino acid change, segregated with autosomal dominant cataract (ADCC) in this family.
  • The altered heat-shock response of mutant cells suggested a change of chaperoning capacity and networking, which could be associated with the pathogenesis of hereditary cataract-microcornea syndrome.

  • MedlinePlus Health Information. consumer health - Cataract.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):471-4 [9467006.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):9951-7 [9296605.001]
  • [Cites] Protein Sci. 2005 Mar;14(3):569-81 [15722442.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):66-78 [15832949.001]
  • [Cites] Mol Vis. 2005;11:321-7 [15889016.001]
  • [Cites] Protein Sci. 2005 Aug;14(8):2030-43 [16046626.001]
  • [Cites] Mol Vis. 2005;11:587-93 [16110300.001]
  • [Cites] Am J Med Genet A. 2006 Mar 15;140(6):558-66 [16470690.001]
  • [Cites] Mol Vis. 2006;12:190-5 [16604058.001]
  • [Cites] Mol Vis. 2006;12:518-22 [16735993.001]
  • [Cites] Mol Vis. 2006;12:768-73 [16862070.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):912-9 [16453125.001]
  • [Cites] Arch Ophthalmol. 2007 Feb;125(2):165-73 [17296892.001]
  • [Cites] Arch Ophthalmol. 2007 Feb;125(2):213-6 [17296897.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1683-90 [17389500.001]
  • [Cites] Biopolymers. 2007 Jun 15;86(3):177-92 [17345631.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3937-44 [17724170.001]
  • [Cites] Mol Vis. 2007;13:2019-22 [17982426.001]
  • [Cites] Am J Ophthalmol. 2007 Dec;144(6):949-952 [17937925.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:47 [18039390.001]
  • [Cites] Semin Cell Dev Biol. 2008 Apr;19(2):134-49 [18035564.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):772-9 [18304496.001]
  • [Cites] Am J Med Genet A. 2008 Apr 1;146A(7):833-42 [18302245.001]
  • [Cites] Acta Ophthalmol Scand. 1999 Oct;77(5):578-80 [10551305.001]
  • [Cites] J Biol Chem. 2000 Feb 11;275(6):3767-71 [10660525.001]
  • [Cites] Biochemistry. 2000 Feb 15;39(6):1420-6 [10684623.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3511-5 [11006246.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1444-8 [11381045.001]
  • [Cites] J Cell Biochem. 2001;82(3):409-14 [11500917.001]
  • [Cites] Eur J Biochem. 2001 Dec;268(24):6335-45 [11737188.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):33-42 [11772997.001]
  • [Cites] J Cell Biochem. 2002;84(2):278-84 [11787056.001]
  • [Cites] Mech Dev. 2002 Mar;112(1-2):213-5 [11850198.001]
  • [Cites] Br J Ophthalmol. 2002 Jul;86(7):782-6 [12084750.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110(10):1041-6 [12361930.001]
  • [Cites] Br J Ophthalmol. 2003 Feb;87(2):197-202 [12543751.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1155-9 [12601044.001]
  • [Cites] Ophthalmic Epidemiol. 2003 Apr;10(2):67-74 [12660855.001]
  • [Cites] Eur J Hum Genet. 2003 Oct;11(10):784-93 [14512969.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 May;45(5):1316-20 [15111583.001]
  • [Cites] Surv Ophthalmol. 2004 May-Jun;49(3):300-15 [15110667.001]
  • [Cites] Science. 1989 Oct 20;246(4928):382-5 [2799391.001]
  • [Cites] Exp Eye Res. 1994 Apr;58(4):381-7 [7925675.001]
  • [Cites] Nature. 1996 Jun 13;381(6583):571-9 [8637592.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):2969-79 [8670798.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20427-34 [9252351.001]
  • [Cites] Mol Vis. 1999 Sep 10;5:21 [10493778.001]
  • (PMID = 19503744.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRYAA protein, human; 0 / Crystallins; 0 / Heat-Shock Proteins
  • [Other-IDs] NLM/ PMC2690964
  •  go-up   go-down


63. Wong AW, Baginski TK, Reilly DE: Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng; 2010 Aug 1;106(5):751-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Removal of the core alpha1,6 fucose from the glycans in the Fc region of IgG1 antibodies has been demonstrated to improve antibody-dependent cellular cytotoxicity (ADCC) activity.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley Periodicals, Inc.
  • (PMID = 20564613.001).
  • [ISSN] 1097-0290
  • [Journal-full-title] Biotechnology and bioengineering
  • [ISO-abbreviation] Biotechnol. Bioeng.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Recombinant Proteins; 9007-49-2 / DNA; EC 2.4.1.- / Fucosyltransferases
  •  go-up   go-down


64. Tang W, Chen G, Gu Q, Pan J, Wu W: Expression, purification and identification of recombinant mouse interleukin 21 protein in E. coli. Cell Mol Immunol; 2006 Aug;3(4):311-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-21 is capable of co-stimulating mature T cells, B cells, NK cells, and of stimulating CD16 expression on the surface of NK cells to induce ADCC in innate immune response.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083198.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukins; 0 / Recombinant Proteins; 0 / interleukin-21
  •  go-up   go-down


65. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS: Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol; 2009 Aug;146(3):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toll-like receptor-9 (TLR-9) agonists have pleotropic effects on both the innate and adaptive immune systems, including increased antigen expression, enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and T helper cell type 1 shift in the immune response.
  • Biologically relevant increases in ADCC and circulating CD-3 positive T cells were observed in 35% and 39% of patients, respectively.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2006 Sep-Oct;29(5):558-68 [16971811.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):276-84 [16916488.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5350-7 [17135637.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):2057-68 [17161362.001]
  • [Cites] Clin Immunol. 2007 Feb;122(2):139-45 [17008130.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97 [17255259.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2008-13 [17068155.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2493-500 [17675511.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6168-74 [17947483.001]
  • [Cites] Exp Hematol. 2008 Jan;36(1):69-77 [17959301.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):161-7 [18176597.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):71-4 [18381100.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):85-9 [18381102.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):902-9 [18464109.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2725-31 [18427151.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3979-86 [18711188.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2644-52 [10914705.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5626-34 [18765557.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):828-34 [12060117.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2253-64 [15073100.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]
  • [Cites] Annu Rev Immunol. 1989;7:145-73 [2523712.001]
  • [Cites] J Cell Biochem. 1991 Apr;45(4):381-90 [1675219.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1059-70 [9276722.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Jan 15;105(2):489-95 [15358617.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1490-9 [15746051.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Cell. 2006 Feb 24;124(4):783-801 [16497588.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • (PMID = 19519691.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 024160; United States / NCI NIH HHS / CA / K23 CA102216; United States / PHS HHS / / A1054953; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / R21 CA103244; United States / NHLBI NIH HHS / HL / HL-007152; United States / NCI NIH HHS / CA / CA-102216; United States / NCI NIH HHS / CA / CA-103244; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NCI NIH HHS / CA / K23 CA102216-05; United States / NIAID NIH HHS / AI / R24 AI054953
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1018 oligonucleotide; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokine CCL2; 0 / Chemokine CXCL10; 0 / IFIT2 protein, human; 0 / Oligodeoxyribonucleotides; 0 / Proteins; 0 / Toll-Like Receptor 9; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS139957; NLM/ PMC2747261
  •  go-up   go-down


66. Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, Badoual C, Varin A, Fisson S, Duvillard P, Boix C, Loncar SM, Sastre-Garau X, Houghton AN, Avril MF, Gresser I, Fridman WH, Sautès-Fridman C: Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer; 2008 Dec 15;123(12):2832-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that FcgammaRIIB expression prevents the lysis of human metastatic melanoma cells by NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in vitro, independently of the intracytoplasmic region of FcgammaRIIB.
  • Using experimental mouse models, we demonstrate that expression of FcgammaRIIB protects B16F0 melanoma tumors from the ADCC induced by monoclonal and polyclonal anti-tumor IgG in vivo.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18798552.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fc gamma receptor IIB; 0 / Immunoglobulin G; 0 / Receptors, IgG
  •  go-up   go-down


67. Sumonwiriya M, Horhthongkham N, Pattanapanyasat K, Ampol S, Sutthent R, Kantakamalakul W: Stable expression of EBV-gp350 on the surface of NC37 cells confers natural killer (NK)-cell susceptibility or resistance, depending on the assay used to assess NK-mediated function. J Virol Methods; 2009 Oct;161(1):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV-gp350 has been identified as a ligand for antibody dependent cell-mediated cytotoxicity (ADCC).
  • The stable expression of gp350 on the NC37 cell surface membrane could make this cell line a suitable target for measuring ADCC antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539652.001).
  • [ISSN] 1879-0984
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromium Radioisotopes; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


68. Xiong Y, Cao C, Makarova A, Hyman B, Zhang L: Mac-1 promotes FcgammaRIIA-dependent cell spreading and migration on immune complexes. Biochemistry; 2006 Jul 25;45(29):8721-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The integrin Mac-1 plays a critical role in Fc receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).
  • Altogether, these results demonstrate that FcgammaRIIA recognizes Mac-1 via the alpha(M)I-domain but not the lectin domain, a distinct feature from other FcRs, and that Mac-1 binding confers FcgammaRIIA with the ability to prolong cell adhesion as well as to spread and migrate on the ICs, leading to effective cell killing by ADCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1993 May;148(2):385-96 [8098672.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5124-9 [14607911.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1407-16 [7515890.001]
  • [Cites] J Biol Chem. 1994 Oct 21;269(42):26419-23 [7929363.001]
  • [Cites] Leuk Res. 1995 Jan;19(1):57-64 [7837818.001]
  • [Cites] J Mol Biol. 1995 Apr 7;247(4):597-603 [7723017.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3281-5 [7561018.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):18211-6 [8663418.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):1184-92 [8757624.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5660-5 [8955219.001]
  • [Cites] Transplantation. 1997 Jan 15;63(1):106-12 [9000670.001]
  • [Cites] Annu Rev Immunol. 1997;15:203-34 [9143687.001]
  • [Cites] J Biol Chem. 1997 Jul 11;272(28):17558-64 [9211902.001]
  • [Cites] J Exp Med. 1997 Dec 1;186(11):1853-63 [9382884.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10556-66 [9553116.001]
  • [Cites] Nat Struct Biol. 1999 May;6(5):437-42 [10331870.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):501-11 [15684035.001]
  • [Cites] Immunity. 2001 Jun;14(6):693-704 [11420040.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Immunol Res. 2002;25(1):75-95 [11868935.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):798-802 [12413532.001]
  • [Cites] Blood. 2003 Jan 1;101(1):253-8 [12485936.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):703-16 [12951577.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2478-86 [11290613.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5629-37 [11313403.001]
  • [Cites] Immunol Lett. 2003 Dec 15;90(2-3):137-43 [14687715.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5437-45 [15466887.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1484-90 [1347707.001]
  • [Cites] J Immunol. 1992 Jun 1;148(11):3550-3 [1534099.001]
  • [Cites] J Cell Biol. 1993 Mar;120(6):1509-17 [8383692.001]
  • [Cites] J Immunol. 1993 Apr 1;150(7):3030-41 [7681086.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4571-80 [8097757.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45720-9 [12941957.001]
  • [Cites] J Leukoc Biol. 1994 Jun;55(6):735-42 [7910840.001]
  • (PMID = 16846215.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL061589; United States / NHLBI NIH HHS / HL / HL061589-05; United States / NHLBI NIH HHS / HL / P01 HL054710; United States / NHLBI NIH HHS / HL / R01 HL061589-05; United States / NHLBI NIH HHS / HL / R01 HL61589-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Antigens, CD; 0 / Fc gamma receptor IIA; 0 / Macrophage-1 Antigen; 0 / Receptors, IgG
  • [Other-IDs] NLM/ NIHMS64482; NLM/ PMC2597675
  •  go-up   go-down


69. Gupta N, Arthos J, Khazanie P, Steenbeke TD, Censoplano NM, Chung EA, Cruz CC, Chaikin MA, Daucher M, Kottilil S, Mavilio D, Schuck P, Sun PD, Rabin RL, Radaev S, Van Ryk D, Cicala C, Fauci AS: Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology; 2005 Feb 20;332(2):491-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adaptive response typically requires that virus-specific antibodies decorate infected cells which then direct NK cell lysis through a CD16 mediated process termed antibody-dependent cellular cytotoxicity (ADCC).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680414.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin G; 0 / Receptors, IgG
  •  go-up   go-down


70. Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA: How can we improve antibody-based cancer therapy? MAbs; 2009 Jan-Feb;1(1):67-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) improvements in biodistribution to maximize delivery of mAbs to susceptible tumor cells; and (3) optimization of antibody immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23514-24 [16793771.001]
  • [Cites] Eur J Nucl Med. 1993 Apr;20(4):345-7 [8491228.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):170-9 [17154393.001]
  • [Cites] Biotechniques. 2005 Oct;39(4):565-8 [16235569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 [16537476.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2178-86 [17332348.001]
  • [Cites] Curr Opin Drug Discov Devel. 2007 Mar;10(2):153-9 [17436550.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8882-90 [17875730.001]
  • [Cites] Drug Discov Today. 2007 Nov;12(21-22):898-910 [17993407.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):453-61 [18287274.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1789-96 [18347005.001]
  • [Cites] Cancer J. 2008 May-Jun;14(3):178-83 [18536557.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3351-7 [18612151.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):366-77 [18596266.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):471-8 [18606225.001]
  • [Cites] Curr Opin Immunol. 2008 Aug;20(4):460-70 [18656541.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26733-40 [11986321.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1485-90 [12459375.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1288-96 [12649189.001]
  • [Cites] Hybrid Hybridomics. 2003 Feb;22(1):1-9 [12713684.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1337-50 [14567626.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):238-44 [6197161.001]
  • [Cites] J Nucl Med. 1990 Jul;31(7):1191-8 [2362198.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(6):351-8 [1652355.001]
  • [Cites] Expert Opin Biol Ther. 2006 Nov;6(11):1161-73 [17049014.001]
  • (PMID = 20046576.001).
  • [ISSN] 1942-0870
  • [Journal-full-title] mAbs
  • [ISO-abbreviation] MAbs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2715179
  • [Keywords] NOTNLM ; biodistribution / bioengineering / cancer / monoclonal antibodies / pharmacogenomics / solid tumors
  •  go-up   go-down


71. Concetti F, Napolioni V: Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy. Recent Pat Anticancer Drug Discov; 2010 Nov;5(3):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanisms behind their efficacy are multi-faceted; they can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis as well as target ligands or growth factor receptors favoring tumor growth.
  • The interaction of the Fc domains of antibodies with the Fcgamma (gamma) receptors is an essential checkpoint in ADCC.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594185.001).
  • [ISSN] 2212-3970
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Receptors, IgG
  •  go-up   go-down


72. Zhang M, Daniel S, Huang Y, Chancey C, Huang Q, Lei YF, Grinev A, Mostowski H, Rios M, Dayton A: Anti-West Nile virus activity of in vitro expanded human primary natural killer cells. BMC Immunol; 2010;11:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expanded NK (D2NK) cell has strong natural killing activity against both K562 and Vero cells, and killed the WNV infected Vero cells through antibody-dependent cellular cytotoxicity (ADCC).

  • Genetic Alliance. consumer health - West nile virus.
  • MedlinePlus Health Information. consumer health - West Nile Virus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Jun;75(12):5663-71 [11356974.001]
  • [Cites] Emerg Infect Dis. 2008 Mar;14(3):436-44 [18325259.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):403-7 [14685783.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):307-14 [15186726.001]
  • [Cites] Acta Virol. 1986 Jul;30(4):303-8 [2876611.001]
  • [Cites] Ann N Y Acad Sci. 1988;540:483-5 [2849899.001]
  • [Cites] J Neuroimmunol. 1989 Feb;21(2-3):157-68 [2463998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(3):911-5 [2492666.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Sci STKE. 2005 Jul 12;2005(292):cm6 [16014603.001]
  • [Cites] Cytotherapy. 2005;7(1):16-22 [16040380.001]
  • [Cites] J Virol. 2006 Jan;80(1):119-29 [16352536.001]
  • [Cites] Transfusion. 2006 Apr;46(4):659-67 [16584445.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):348-58 [16893656.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):367-82 [16934486.001]
  • [Cites] Viral Immunol. 2003;16(3):259-78 [14583143.001]
  • (PMID = 20089143.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Receptors, Natural Killer Cell; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2822749
  •  go-up   go-down


73. Zhu HL, Li Y, Chang XH, Cui H, Feng J, Wei LH: [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jan;41(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].
  • Anti-anti-idiotypic antibody (Ab3) level was tested and antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effect of mouse spleen cells to human ovarian carcinoma SKOV3 cells were measured using (51)Cr-release assay.
  • At four different effector cell/target cell (E/T) ratios, the ADCC was highest in group A and lowest in group C; when the E/T ratio was 1:125, (51)Cr releasing rate was 23% in group A, 17% in group B, and 12% in group C, the difference between groups A, B, C had statistical significance (P < 0.05).
  • CONCLUSION: 6B11 anti-idiotypic minibody of ovarian carcinoma can be used as tumor vaccine, the suitable immunization protocol in animals may be: prime at d(1), d(14) and d(28) at a dose of 100 microg; prime interval is six weeks.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635330.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines
  •  go-up   go-down


74. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res; 2005 Nov 15;65(22):10562-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data indicate a crucial role for antibody-dependent cell-mediated cytoxicity (ADCC).
  • However, at lower doses of IgG, therapeutic effect was partially abrogated in C3-deficient mice, indicating complement-mediated enhancement of ADCC at limiting IgG concentration.
  • Thus, IgG and IgM can operate via different primary mechanisms of action, and CDCC and complement-dependent enhancement of ADCC mechanisms are operative in vivo.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288049.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / AT002779; United States / NCI NIH HHS / CA / CA104579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD2; 0 / Antigens, CD59; 0 / Complement C3; 0 / Immunoglobulin M; 0 / Receptors, IgG; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


75. Saghravanian N, Mohtasham N, Jafarzadeh H: Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. J Oral Sci; 2009 Dec;51(4):509-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
  • Adenoid cystic carcinoma (AdCC) and polymorphous low-grade adenocarcinoma (PLGA) have several common histological and clinicopathological features that may create diagnostic difficulties.
  • In this study, 10 AdCCs, 8 PLGAs, and 5 normal minor salivary glands as a control group were selected.
  • Data analysis showed high expression of CEA, MSA and Ki-67 in AdCCs compared with PLGAs, although CEA expression was limited to luminal cells.
  • The immunoreactivities of EMA and P53 were not helpful for distinguishing between the two tumors, although the EMA expression pattern in AdCCs was limited to luminal cells, whereas it was present in both luminal and non-luminal cells in PLGAs.
  • Thus, immunohistochemistry can be helpful for differential diagnosis of AdCC and PLGA, particularly that for CEA, vimentin, and Ki-67.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor. Carcinoma, Adenoid Cystic / chemistry. Salivary Gland Neoplasms / chemistry


76. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene; 2005 Mar 24;24(13):2121-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested.


77. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH: In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res; 2010 Apr 15;70(8):3209-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effector cell activation through FcR triggering may induce tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC).
  • In contrast, ADCC of cells expressing frequently used cancer targets, such as CD20, epidermal growth factor receptor, Her2, and gp75, was abrogated.
  • ADCC therefore represents an essential mechanism of action for immunotherapy of lymphoid tumors.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • (PMID = 20354182.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 06-0368
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Receptors, Fc; 4F4X42SYQ6 / Rituximab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; M95KG522R0 / ofatumumab
  •  go-up   go-down


78. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M: Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol; 2006 Sep 15;177(6):4028-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, Ab-dependent cellular cytotoxicity (ADCC) was significantly correlated with reduced acute viremia upon intrarectal SIVmac251 challenge of immunized rhesus macaques.
  • To directly assess ADCC protective efficacy, six neonatal macaques were infused s.c. with immune IgG (220 mg/kg) purified from the immunized animals and positive for ADCC and Ab-dependent cell-mediated viral inhibition (ADCVI) activities.
  • At challenge, plasma of neonates that received immune IgG did not neutralize SIVmac251 but had geometric mean ADCC titers of 48,130 and 232,850 against SIVmac251 -infected and gp120-coated targets, respectively.
  • ADCC activity declined with the 2-wk IgG half-life but was boosted at wk 4, together with de novo ADCC-mediating Abs in controls, by postchallenge viremia.
  • Possible factors contributing to the discrepancy between the previous correlation and lack of protection here include: the high oral challenge dose compared with the 400-fold lower intrarectal dose; the challenge route with regard to viral dissemination and distribution of infused IgG; insufficient NK effector activity and/or poor functionality in newborns; insufficient immune IgG; and the possibility that the previous correlation of ADCC with protection was augmented by cellular immune responses also present at challenge.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951366.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R02 AI52039; United States / NCRR NIH HHS / RR / RR00169; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


79. Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R: The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia; 2006 Dec;20(12):2162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore tested the chimeric anti-CCR4 monoclonal antibody (mAb), KM2760, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity (ADCC), as a novel immunotherapy for refractory HL.
  • Although KM2760 did not induce any ADCC mediated by mouse natural killer (NK) cells, it significantly enhanced phagocytosis mediated by mouse monocytes/macrophages against the CCR4-positive HL cell line in vitro.
  • Furthermore, it induced robust ADCC mediated by NK cells against the CCR4-positive HL cell line in vitro.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039235.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCR4 protein, human; 0 / Ccr4 protein, mouse; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


80. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J: Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res; 2009 Oct 15;69(20):8058-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is thought to contribute to the therapeutic effects of trastuzumab, we have established a cell culture system to select for ADCC-resistant SK-OV-3 ovarian cancer and MCF7 mammary carcinoma cells.
  • When immunoselected MCF7 cells were then re-expanded, they mostly lost the observed phenotype to regenerate a tumor cell culture that displayed the initial HER2 surface expression and ADCC-susceptibility, but was enriched in CD44(high)CD24(low) cancer stem cells.
  • Thus, we provide evidence that the induction of ADCC by trastuzumab and NK cells may spare the actual tumor-initiating cells, which could explain clinical relapse and progress.
  • Moreover, our observation that the "relapsed" in vitro cultures show practically identical HER2 surface expression and susceptibility toward ADCC suggests that the administration of trastuzumab beyond relapse might be considered, especially when combined with an immune-stimulatory treatment that targets the escape variants.


81. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood; 2008 Dec 15;112(13):5180-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL).
  • We therefore examined whether lenalidomide combined with rituximab enhances direct apoptosis and ADCC in CLL cells.
  • In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Ther Drug Monit. 2008 Oct;30(5):620-7 [18708993.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Eur J Immunol. 2003 Sep;33(9):2398-409 [12938216.001]
  • [Cites] Haematologica. 2003 Sep;88(9):1002-12 [12969808.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1846-54 [14630799.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):895-913, ix-x [15325705.001]
  • [Cites] Int J Cancer. 1981 Mar 15;27(3):321-7 [6169660.001]
  • [Cites] Scand J Haematol. 1981 Sep;27(3):181-5 [6947403.001]
  • [Cites] Blood. 1984 Feb;63(2):305-9 [6607080.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2589-92 [4031496.001]
  • [Cites] J Biol Chem. 1986 Aug 5;261(22):10240-7 [3733709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):8085-9 [3500472.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Acta Haematol. 1996;96(1):16-23 [8677756.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):478-83 [9716030.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5984-92 [16115943.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1675-82 [16030029.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4050-3 [16118317.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11712-20 [16357183.001]
  • [Cites] Leukemia. 2006 Feb;20(2):272-9 [16341049.001]
  • [Cites] J Control Release. 2006 May 15;112(2):199-207 [16564596.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):480-8 [16750498.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8653-61 [17875705.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2561-4 [17475906.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):36-45 [17995965.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [CommentIn] Blood. 2008 Dec 15;112(13):4785-6 [19064733.001]
  • [ErratumIn] Blood. 2009 Oct 15;114(16):3506
  • (PMID = 18772452.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / CA95426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2597613
  •  go-up   go-down


82. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Medical records of patients with the diagnosis of ADCC between 1990 and 2000 were reviewed.
  • Survival for ADCC is poor.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K: Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods; 2005 Nov 30;306(1-2):93-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fucose removal from complex-type oligosaccharide of human IgG1-type antibody results in a great enhancement of antibody-dependent cellular cytotoxicity (ADCC).
  • The scFv-Fc lacking fucose exhibited significantly more potent FcgammaRIIIa binding and ADCC compared to highly fucosylated scFv-Fc.
  • These results prove that ADCC enhancement by fucose-removal is effective in not only whole IgG1, but also scFv-Fc, and thus increases the potential of Fc-fusion proteins as therapeutic candidates.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236307.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / Immunoglobulin Constant Regions; 0 / Immunoglobulin G; 0 / Immunoglobulin Variable Region; 0 / Oligosaccharides; 0 / Receptors, IgG; 0 / Recombinant Fusion Proteins; 0 / tumor-associated antigen 72; 3713-31-3 / Fucose; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase
  •  go-up   go-down


84. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S: Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One; 2010 Nov 09;5(11):e13916
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-1 Env-specific binding antibody, neutralizing antibody, antibody-dependent cell-mediated cytotoxicity (ADCC), and profiles of antibody specificity were analyzed for human immune sera collected from vaccinees enrolled in the NIH HIV Vaccine Trial Network (HVTN) Study #041 (recombinant protein alone), HVTN Study #203 (poxviral vector prime-protein boost), and the DP6-001 study (DNA prime-protein boost).
  • No differences were found in CD4-induced (CD4i) antibody responses, ADCC activity, or complement activation by Env-specific antibody among these sera.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):207-10 [10655111.001]
  • [Cites] Science. 2010 Aug 13;329(5993):811-7 [20616231.001]
  • [Cites] Virology. 2001 Dec 20;291(2):324-34 [11878901.001]
  • [Cites] J Med Primatol. 2002 Jun;31(3):109-19 [12190851.001]
  • [Cites] J Virol. 2003 Jun;77(11):6466-73 [12743303.001]
  • [Cites] Nature. 1992 Feb 20;355(6362):728-30 [1741059.001]
  • [Cites] J Virol. 1996 Oct;70(10):6751-8 [8794312.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1230-46 [9593008.001]
  • [Cites] J Virol. 1999 May;73(5):4009-18 [10196297.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):654-65 [15688278.001]
  • [Cites] Vaccine. 2005 Mar 31;23(19):2522-9 [15752839.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1407-19 [15867093.001]
  • [Cites] J Virol. 2005 Aug;79(16):10108-25 [16051804.001]
  • [Cites] J Virol. 2005 Dec;79(24):15547-55 [16306625.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):53-67 [16343526.001]
  • [Cites] Arch Virol. 2006 Aug;151(8):1511-23 [16508703.001]
  • [Cites] J Virol. 2006 Sep;80(17):8745-62 [16912322.001]
  • [Cites] Expert Rev Vaccines. 2006 Aug;5(4):579-95 [16989638.001]
  • [Cites] Hum Vaccin. 2005 Mar-Apr;1(2):45-60 [17038830.001]
  • [Cites] Vaccine. 2007 Jan 5;25(3):510-8 [17049679.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12 [17106277.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1032-4 [17721546.001]
  • [Cites] Virology. 2007 Sep 30;366(2):245-62 [17580087.001]
  • [Cites] Vaccine. 2008 Jul 23;26(31):3947-57 [18724414.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):613-9 [18833271.001]
  • [Cites] PLoS Pathog. 2008;4(10):e1000171 [18833294.001]
  • [Cites] Virology. 2008 Oct 25;380(2):285-95 [18804254.001]
  • [Cites] J Virol. 2008 Dec;82(23):11651-68 [18815292.001]
  • [Cites] Lancet. 2008 Nov 29;372(9653):1881-93 [19012954.001]
  • [Cites] J Virol. 2009 Jan;83(2):1045-59 [19004942.001]
  • [Cites] Nature. 2009 Apr 2;458(7238):636-40 [19287373.001]
  • [Cites] Nat Med. 2009 Aug;15(8):951-4 [19525965.001]
  • [Cites] Science. 2009 Oct 9;326(5950):285-9 [19729618.001]
  • [Cites] N Engl J Med. 2009 Dec 3;361(23):2209-20 [19843557.001]
  • [Cites] J Virol. 2001 Aug;75(16):7470-80 [11462019.001]
  • (PMID = 21085486.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI082274; United States / NIAID NIH HHS / AI / AI082676; United States / NIAID NIH HHS / AI / AI065250; United States / NIAID NIH HHS / AI / U19 AI082676; United States / NIAID NIH HHS / AI / R01 AI065250; United States / NIAID NIH HHS / AI / P01 AI082274; United States / NIAID NIH HHS / AI / U01 AI068618; United States / NIAID NIH HHS / AI / P30 AI027742; United States / NIAID NIH HHS / AI / R21 AI087191; United States / NIAID NIH HHS / AI / AI 27742
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / Antibodies, Neutralizing; 0 / HIV Antibodies; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2976701
  •  go-up   go-down


85. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, Goletz S: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother; 2006 Nov;55(11):1337-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PankoMab reveals a potent tumour-specific antibody-dependent cell cytotoxicity (ADCC).
  • PankoMab is, therefore, distinguished by a combination of advantages compared to other MUC1 antibodies in clinical development, including higher tumour specificity, higher affinity, a higher number of binding sites, largely reduced binding to shed MUC1 from colon and pancreatic carcinoma patients, no binding to mononucleated cells from peripheral blood (except approximately 7% of activated T cells), stronger ADCC activity and rapid internalisation as required for toxin-mediated cell killing.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485130.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Carbohydrates; 0 / Epitopes; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


86. Ide F, Mishima K, Yamada H, Saito I: Adenoid cystic carcinoma ex pleomorphic adenoma of the parotid gland. Head Neck Pathol; 2009 Jun;3(2):159-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma ex pleomorphic adenoma of the parotid gland.
  • There is a considerable variation in the histologic subtype of epithelial malignancies among carcinoma ex pleomorphic adenomas (CXPA) and virtually any known carcinoma entity can develop.
  • To our knowledge, adenoid cystic carcinoma (AdCC) ex PA is quite rare despite the fact that de novo AdCC is the fourth most common salivary gland malignancy.
  • We describe a new case of AdCC ex PA in the parotid gland of a 62 year-old woman.
  • Although most of the reported cases are considered low-grade, evidence is presented here that AdCC can take the form of a high-grade malignancy in PA.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma, Adenoid Cystic / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otolaryngol. 1968 Dec;66(6):477-92 [4308066.001]
  • [Cites] Cancer. 1968 Jun;21(6):1198-211 [4296747.001]
  • [Cites] Cancer. 1977 May;39(5):2209-30 [192443.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1985;86(1):36-40 [2984762.001]
  • [Cites] Acta Cytol. 1985 Jul-Aug;29(4):522-6 [2992197.001]
  • [Cites] Pathol Annu. 1993;28 Pt 1:279-328 [8380049.001]
  • [Cites] Auris Nasus Larynx. 1995;22(1):65-70 [7677639.001]
  • [Cites] Histopathology. 1996 Mar;28(3):247-52 [8729044.001]
  • [Cites] J Otolaryngol. 1999 Jun;28(3):166-70 [10410350.001]
  • [Cites] Histopathology. 2005 Jun;46(6):635-41 [15910594.001]
  • [Cites] J Craniofac Surg. 2007 Jan;18(1):231-5 [17251870.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):79-84 [17049779.001]
  • [Cites] Histopathology. 2007 Jul;51(1):1-20 [17539914.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 May;138(5):601-5 [18439465.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2002 Mar;24(3):301-6 [11891964.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):724-33 [12118110.001]
  • [Cites] Pathol Int. 2003 Jan;53(1):30-4 [12558867.001]
  • [Cites] Rhinology. 2003 Jun;41(2):118-21 [12868379.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Cancer. 1977 Feb;39(2):388-96 [189890.001]
  • (PMID = 19644550.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Carcinoma ex pleomorphic adenoma / High-grade malignancy / Parotid gland
  •  go-up   go-down


87. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS, Thai AIDS Vaccine Evaluation Group, Thailand: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine; 2005 Mar 31;23(19):2522-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine trial in Thailand.
  • ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients.
  • There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients.
  • The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.


88. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M: Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol; 2008 Jul;61(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological and molecular features of adrenocortical carcinoma: an update.
  • The pathological diagnosis of adrenocortical carcinoma (ACC), which is based on gross and microscopic criteria, is subjective.
  • The classification of oncocytic and paediatric adrenocortical tumours is even more challenging, as not all of the above morphological parameters are predictors of malignancy in these tumour types.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Algorithms. Biomarkers, Tumor / metabolism. Chromosome Aberrations. Diagnosis, Differential. Humans. Immunophenotyping. Neoplastic Syndromes, Hereditary / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430754.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 75
  •  go-up   go-down


89. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R: Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res; 2008 May 15;68(10):3863-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that fucose removal from Fc-linked oligosaccharides greatly enhances antibody-dependent cellular cytotoxicity (ADCC) of therapeutic antibodies.
  • To eliminate this deficiency, a portion in COOH-terminal CH3 domain of 1133 was substituted with IgG1, resulting in full recovery of protein A binding without compromising the enhanced CDC and ADCC activities.
  • The ADCC activity of the variants was also maximized by the absence of fucose from its carbohydrate structure, a phenomenon that has previously been observed for wild-type antibodies.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483271.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Immunoglobulin Isotypes
  •  go-up   go-down


90. Manu KA, Kuttan G: Effect of Punarnavine, an alkaloid from Boerhaavia diffusa, on cell-mediated immune responses and TIMP-1 in B16F-10 metastatic melanoma-bearing mice. Immunopharmacol Immunotoxicol; 2007;29(3-4):569-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of Punarnavine enhanced Natural Killer (NK) cell activity, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent complement mediated cytotoxicity (ACC) and the activity was observed in treated group much earlier compared to the metastatic tumor-bearing control.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075866.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / DNA Primers; 0 / Interleukin-1beta; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Necrosis Factor-alpha; 0 / punarnavine; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


91. Beuger V, Künkele KP, Koll H, Gärtner A, Bähner M, Burtscher H, Klein C: Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. Biotechnol Appl Biochem; 2009 May;53(Pt 1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-producing Chinese-hamster ovary cells (CHO-DG44) were converted into cells producing antibodies with strongly enhanced ADCC (antibody-dependent cellular cytotoxicity) by knocking down FuT8 (alpha-1,6-fucosyltransferase or fucosyltransferase 8) via constitutive expression of shRNA (short-hairpin RNA) against FuT8.
  • The CHO-DG44 clones identified produced highly afucosylated anti-[IGF-1R (insulin-like-growth-factor-1 receptor)] antibodies (up to 88%) that exhibited considerably enhanced ADCC compared with anti-IGF-1R wild-type antibodies produced by parental CHO cells.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032154.001).
  • [ISSN] 1470-8744
  • [Journal-full-title] Biotechnology and applied biochemistry
  • [ISO-abbreviation] Biotechnol. Appl. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


92. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA: TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol; 2008 Sep 15;181(6):3784-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of TGF-beta in regulating CD16-mediated NK cell IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is unclear, as are the signaling pathways that may be utilized.
  • An extended treatment of primary NK cells with TGF-beta was required to inhibit ADCC, and it did so by inhibiting granzyme A and granzyme B expression.
  • Collectively, our results indicate that TGF-beta inhibits CD16-mediated human NK cell IFN-gamma production and ADCC, and these effects are mediated via SMAD3.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1027-35 [9064320.001]
  • [Cites] Immunity. 1997 Jun;6(6):655-61 [9208838.001]
  • [Cites] Curr Top Microbiol Immunol. 1998;230:63-88 [9586351.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6648-56 [9862693.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2974-81 [10072548.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4511-20 [10201989.001]
  • [Cites] J Immunol Methods. 2005 Jan;296(1-2):115-23 [15680156.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3011-8 [15604218.001]
  • [Cites] Nat Immunol. 2005 Jun;6(6):600-7 [15852008.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):349-50 [16286241.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):517-26 [16397268.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):179-86 [8551221.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2409-14 [16304057.001]
  • [Cites] Annu Rev Immunol. 2006;24:99-146 [16551245.001]
  • [Cites] Int Immunopharmacol. 2006 Jun;6(6):1020-8 [16644489.001]
  • [Cites] Immunity. 2006 May;24(5):575-90 [16713975.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):120-9 [16785506.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3993-6 [16818697.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4142-6 [16857784.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7046-53 [17145827.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Eur J Immunol. 2007 Sep;37(9):2549-61 [17705132.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3192-201 [17616639.001]
  • [Cites] Blood. 2008 May 1;111(9):4723-30 [18182577.001]
  • [Cites] Microbes Infect. 1999 Dec;1(15):1305-11 [10611759.001]
  • [Cites] Cell. 2000 Mar 17;100(6):655-69 [10761931.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1782-9 [10925255.001]
  • [Cites] Blood. 2001 May 15;97(10):3146-51 [11342442.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Eur J Immunol. 2001 Oct;31(10):3016-25 [11592078.001]
  • [Cites] Trends Immunol. 2001 Nov;22(11):633-40 [11698225.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Mol Pharmacol. 2002 Jul;62(1):65-74 [12065756.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):983-92 [12370276.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):145-60 [12620409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5 [12646700.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4572-7 [12707335.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1745-50 [1281217.001]
  • [Cites] Scand J Immunol. 1993 Jan;37(1):71-6 [8380302.001]
  • [Cites] J Immunol. 1993 Jan 15;150(2):605-16 [8419492.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):551-8 [8294866.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1066-73 [7636180.001]
  • (PMID = 18768831.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA68458; United States / NCI NIH HHS / CA / R01 CA068458; United States / NCI NIH HHS / CA / R01 CA095512; United States / NCI NIH HHS / CA / P01 CA095426-09; United States / NCI NIH HHS / CA / R01 CA095512-08; United States / NCI NIH HHS / CA / CA016058-30; United States / NCI NIH HHS / CA / CA095512-08; United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / CA095512; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA068458-08S1; United States / NCI NIH HHS / CA / CA95426; United States / NCI NIH HHS / CA / CA095426-09; United States / NCI NIH HHS / CA / R37 CA068458; United States / NCI NIH HHS / CA / R01 CA068458-08S1; United States / NCI NIH HHS / CA / P30 CA016058-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FCGR3B protein, human; 0 / GPI-Linked Proteins; 0 / Receptors, IgG; 0 / SMAD3 protein, human; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS215048; NLM/ PMC2924753
  •  go-up   go-down


93. Clark AJ, Diamond M, Elfline M, Petty HR: Calicum microdomains form within neutrophils at the neutrophil-tumor cell synapse: role in antibody-dependent target cell apoptosis. Cancer Immunol Immunother; 2010 Jan;59(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophil-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is one form of leukocyte activation that plays an important role in tumor cell killing in vitro and in patient care.
  • Using fluorescence methodologies, we found that neutrophils exhibit Ca(2+) signals during ADCC directed against breast fibrosarcoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):690-702 [17703229.001]
  • [Cites] Methods Mol Biol. 2008;414:13-21 [18175808.001]
  • [Cites] J Lipid Res. 2008 Mar;49(3):531-42 [18156590.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1789-96 [18347005.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17333-40 [18430726.001]
  • [Cites] Cytometry A. 2008 Jul;73(7):673-8 [18496849.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):124-34 [19185847.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1122-9 [19164213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15217-21 [10611365.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Blood. 2001 Jan 15;97(2):339-45 [11154206.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2478-86 [11290613.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):522-30 [11310837.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1643-53 [11309196.001]
  • [Cites] Vox Sang. 2001;81(2):128-33 [11555474.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):707-12 [11792958.001]
  • [Cites] Immunol Res. 2002;25(1):75-95 [11868935.001]
  • [Cites] Blood. 2003 Jan 1;101(1):253-8 [12485936.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):537-50 [12508114.001]
  • [Cites] Annu Rev Immunol. 2003;21:457-81 [12615889.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5124-9 [14607911.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8619-27 [14634623.001]
  • [Cites] J Immunol. 1979 Jul;123(1):55-62 [36434.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):331-9 [6205210.001]
  • [Cites] J Immunol. 1988 May 15;140(10):3515-21 [2966198.001]
  • [Cites] J Cell Physiol. 1989 Dec;141(3):598-605 [2687299.001]
  • [Cites] Am Rev Respir Dis. 1990 Mar;141(3 Pt 2):S127-31 [2178532.001]
  • [Cites] Scand J Immunol. 1990 Mar;31(3):315-25 [2157275.001]
  • [Cites] J Leukoc Biol. 1991 May;49(5):511-24 [1826726.001]
  • [Cites] Immunology. 1991 Dec;74(4):657-60 [1838354.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1484-90 [1347707.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1609-14 [7595233.001]
  • [Cites] J Histochem Cytochem. 1996 Jun;44(6):641-56 [8666749.001]
  • [Cites] J Leukoc Biol. 1996 Oct;60(4):433-40 [8864126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14809-14 [8962137.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):696-701 [9044847.001]
  • [Cites] Blood. 1997 May 15;89(10):3503-21 [9160655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6 [9435247.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3051-8 [9679970.001]
  • [Cites] Neuroreport. 1999 Apr 6;10(5):1149-53 [10321500.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3516-21 [15569668.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:269-90 [15822178.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):156-65 [15916759.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):37-51 [17222789.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6210-21 [17202140.001]
  • [Cites] Sci STKE. 2007 Apr 10;2007(381):pe14 [17426345.001]
  • [Cites] Curr Biol. 2007 Jun 19;17(12):1076-81 [17570667.001]
  • [Cites] Drug Discov Today. 2007 Nov;12(21-22):898-910 [17993407.001]
  • (PMID = 19593564.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Membrane Glycoproteins; 0 / Stim1 protein, mouse; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS381280; NLM/ PMC3379002
  •  go-up   go-down


94. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR: Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther; 2008 Aug;7(8):2517-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although an early goal has been enhanced FcgammaRIIIa binding and natural killer (NK) cell antibody-dependent cell-mediated cytotoxicity (ADCC), other relevant cell types such as macrophages are dependent on additional activating receptors such as FcgammaRIIa.
  • Specific double and triple combination variants with this substitution are simultaneously capable of exhibiting high NK-mediated ADCC and high macrophage phagocytosis.

  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723496.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Fc gamma receptor IIA; 0 / Receptors, IgG
  •  go-up   go-down


95. Biglari A, Southgate TD, Fairbairn LJ, Gilham DE: Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. Gene Ther; 2006 Apr;13(7):602-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC) is one means by which macrophages (as well as natural killer cells and granulocytes) elicit a cytotoxic response.

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397508.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Cytokines; 0 / Receptors, IgG; 0 / Recombinant Proteins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


96. Guerrero MA, Kebebew E: Adrenocortical carcinoma and synchronous malignancies. J Cancer; 2010;1:108-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma and synchronous malignancies.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is an aggressive tumor that accounts for 0.02% of all reported cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842232.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2938073
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / Ovarian cancer / Synchronous malignancies / Uterine cancer / and Hereditary syndrome
  •  go-up   go-down


97. Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M: A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods; 2006 Jan 20;308(1-2):53-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used the RFADCC to assess dose-dependent and envelope-specific anti-human immunodeficiency virus (HIV) ADCC responses mediated by monoclonal antibody-2G12 and human sera.
  • Using the assay, we also detected early anti-simian immunodeficiency virus (SIV) ADCC responses in rhesus macaques infected with pathogenic SIV(mac251).
  • Importantly, the RFADCC was further useful in monitoring anti-HIV and anti-SIV ADCC responses elicited by immunizing chimpanzees and rhesus macaques with replicating adenovirus-based AIDS vaccine candidates.
  • The RFADCC is therefore a simple, reliable, and highly sensitive method that can be applied to assess the ADCC activity of monoclonal antibodies as well as ADCC responses elicited by HIV or SIV infection or by AIDS vaccine candidates.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343526.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 5-(6)-carboxyfluorescein diacetate succinimidyl ester; 0 / AIDS Vaccines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Viral; 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Organic Chemicals; 0 / PKH 26; 0 / Succinimides; 0R0008Q3JB / Chromium
  •  go-up   go-down


98. Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ: [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng; 2007 Aug;26(8):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Natural killer (NK) cells are the main effector of antibody-dependent cellular cytotoxicity (ADCC).

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697543.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


99. Shitara K: [Potelligent antibodies as next generation therapeutic antibodies]. Yakugaku Zasshi; 2009 Jan;129(1):3-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-dependent cellular cytotoxicity (ADCC), a lytic attack on antibody-targeted cells, is triggered upon binding of lymphocyte receptors (FcgammaRs) to the antibody constant region.
  • ADCC is considered to be a major therapeutic function of antibodies.
  • ADCC requires the presence of oligosaccharides in the Fc region and is sensitive to change in the oligosaccharide structure.
  • We have demonstrated that fucose is the most critical IgG1 oligosaccharide component, and the removal of fucose from IgG1 oligosaccharides results in a very significant enhancement of ADCC and anti-tumor activity in vivo.
  • Potelligent antibodies show potent ADCC upon target cells through the effective and antigen-specific activation of NK cells due to augmented binding to FcgammaRIIIa.
  • Moreover, Potelligent antibodies can evade the inhibitory effect of plasma IgG on ADCC through its high FcgammaRIIIa binding.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122430.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / FCGR3A protein, human; 0 / Immunoglobulin G; 0 / Oligosaccharides; 0 / Receptors, IgG; 3713-31-3 / Fucose
  • [Number-of-references] 19
  •  go-up   go-down


100. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ: V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Int J Cancer; 2008 Jun 1;122(11):2526-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V gamma 9 V delta 2 T cells expanded in the presence of Zoledronate and IL-2 express CD16 (Fc gamma RIII), which raises the possibility that V gamma 9 V delta 2 T cells could be used in conjunction with tumor targeting monoclonal antibody drugs to increase antitumor cytotoxicity by antibody dependent cellular cytotoxicity (ADCC).
  • Our results show that CD16(+)V gamma 9 V delta 2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or V gamma 9 V delta 2 T cells alone.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2011 Dec 1;129(11):2761. Fai-So, Hang [corrected to So, Hang-Fai]
  • (PMID = 18307255.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Chemokines; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, IgG; 126465-35-8 / Perforin; 4F4X42SYQ6 / Rituximab; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down






Advertisement